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Abstract
In spite of the huge success of the standard single-nucleotide polymorphism (SNP)
based analysis in genome-wide association studies (GWASs), it has some limitations.
First, it suffers power loss from a stringent significance level due to multiplicity adjust-
ment for up to millions of tests. In addition, it has low power since the effect sizes of
SNPs are usually small. Instead, gene-based testing might improve statistical power
by aggregating moderate to weakly associated SNPs within each gene while greatly re-
ducing the burden of multiple testing adjustment from millions to thousands. Second,
almost all existing analyses do not explicitly account for (unknown) genetic hetero-
geneity, leading to possible loss of power as convincingly shown in simulation studies
(Londono et al., 2012; Qian and Shao, 2013; Zhou and Pan, 2009). Moreover, as there
are many other data resources available (e.g. neuroimaging phenotypes, molecular phe-
notypes like gene expression) besides GWAS/DNA sequencing data, integrating them
into GWAS is expected to boost statistical power.
We first introduce a flexible framework to extend score-based testing in generalized
linear models to more complex models, for example, mixed effect models. Second, we
show that by accounting for genetic heterogeneity, more associated SNPs can be detected
than the standard one-degree-of-freedom trend test in single SNP-based testing. Third,
we propose a new adaptive aSPC test to detect associations between two random vectors
in moderate to high dimensions; we also point out its connections to some existing
association testing for multiple SNPs and multiple traits. Finally, we propose a novel
gene-based association testing approach by incorporating weights derived from other
data resources (e.g. from another eQTL dataset). We show the power gain of the
new approach over two existing methods PrediXcan and TWAS, pointing out that both
PrediXcan and TWAS are special cases of our new test.
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Chapter 1
Introduction
1.1 Background
Neuroimaging genetics has been increasingly drawn attention because of its usefulness to
understand the mechanism of diseases. For example, Alzhemer’s Disease Neuroimaging
Initiative (ADNI) is a national-wide longitudinal study with large amount of clinical,
imaging, genetic and biochemical biomarker data collected for the early detection and
tracking of Alzheimer’s disease (AD). This thesis focuses on developing powerful statis-
tical testing methods to detect associations between genetic variants and phenotypes of
interest (e.g. disease status or neuroimaging traits).
In spite of the success of single SNP association analysis, it might be too conserva-
tive as there are hundreds of millions tests needed to be adjusted. Instead, gene-based
testing might improve power as it greatly reduces the burden of multiple tests adjust-
ment from millions to thousands. In neuroimaging studies, hundreds and thousands of
secondary neuroimaging phenotypes are measured (e.g. grey matter density of a re-
gion of interest in human brain); conducting association analysis for these multiple and
correlated phenotypes are of interest.
We first point out the limitation of existing score-based testings and extend them to
complex models by approximating score vectors. For genome-wide association studies
and DNA sequencing studies, several powerful score-based tests, such as kernel machine
regression and sum of powered score tests, have been proposed in the last few years.
1
2However, extensions of these score-based tests to more complex models, such as mixed-
effects models for analysis of multiple and correlated traits, have been hindered by the
unavailability of the score vector, due to either no output from statistical software or no
closed-form solution at all. We propose a simple and general method to asymptotically
approximate the score vector based on an asymptotically normal and consistent estimate
of a parameter vector to be tested and its (consistent) covariance matrix. The proposed
method is applicable to both maximum-likelihood estimation and estimating function-
based approaches. We use the derived approximate score vector to extend several score-
based tests to mixed-effects models. We demonstrate the feasibility and possible power
gains of these tests in association analysis of multiple and correlated quantitative or
binary traits with both real and simulated data. The proposed method is easy to
implement with a wide applicability.
Second we emphasize the potential usefulness of accounting for genetic heterogeneity
in GWASs. GWASs have confirmed the ubiquitous existence of genetic heterogeneity
for common disease: multiple common genetic variants have been identified to be as-
sociated, while many more are yet expected to be uncovered. On the other hand, the
single SNP-based trend test (or its variants) that has been dominantly used in GWASs
is based on contrasting the allele frequency difference between the case and control
groups, completely ignoring possible genetic heterogeneity. In spite of the widely ac-
cepted notion of genetic heterogeneity, we are not aware of any previous attempt to
apply genetic heterogeneity-motivated methods in GWAS. Here, to explicitly account
for unknown genetic heterogeneity, we applied a mixture model-based single SNP test to
the WTCCC GWAS data with traits Crohn’s disease, bipolar disease, coronary artery
disease and type 2 diabetes, identifying much larger numbers of significant SNPs and
risk loci for each trait than those of the popular trend test, demonstrating potential
power gain of the mixture model-based test.
Third we propose an association testing method between two random vectors, which
can be applied in testing associations between multiple neuroimaging phenotypes and
genetic variants. Testing association between two random vectors is a common and
important task in many fields, however, existing tests, such as the RV test, are suitable
only for low-dimensional data, not for high-dimensional data. In moderate to high
dimensions, it is necessary to consider sparse signals, which are often expected with
3only a few, but not many, variables associated with each other. We generalize the
RV test to moderate to high dimensions. The key idea is to data-adaptively weight
each variable pair based on its empirical association. As the consequence, the proposed
test is adaptive, alleviating the effects of noise accumulation in high-dimensional data,
and thus maintaining the power for both dense and sparse alternative hypotheses. We
show the connections between the proposed test with several existing tests, such as
a GEE-based adaptive test, multivariate kernel machine regression and kernel distance
methods. Furthermore, we modify the proposed adaptive test so that it can be powerful
for non-linear or non-monotonic associations. We use both real data and simulated data
to demonstrate the advantages and usefulness of the proposed new test.
Finally we introduce a novel gene-based testing by incorporating weights from other
data sources (e.g. gene-expression). Two new gene-based association analysis methods,
called PrediXcan and TWAS for GWAS individual-level and summary data respectively,
were recently proposed to integrate GWAS with eQTL data, alleviating two common
problems in GWAS by boosting statistical power and facilitating biological interpreta-
tion of GWAS discoveries. Based on a novel reformulation of PrediXcan and TWAS,
we propose a more powerful gene-based association test to integrate single set or mul-
tiple sets of eQTL data with GWAS individual-level data or summary statistics. The
proposed test was applied to several GWAS datasets, including two lipid summary asso-
ciation datasets based on ∼ 100, 000 and ∼ 189, 000 samples respectively, and uncovered
more known or novel trait-associated genes, showcasing much improved performance of
our proposed method.
The rest of the thesis is organized as follows. Chapter 2 discusses the limitation of
the existing score-based tests and how we can extend them to more complex models. In
Chapter 3, we point out the potential power gains by accounting genetic heterogeneity
in GWASs. Chapter 4 introduces a method to test association between two random
vectors in moderate to high dimension, which can be applied to test associations between
multi-SNP and multi-phenotypes. Finally in Chapter 5, we propose a novel gene-based
association testing by incorporating weights derived from other data resources (e.g.
gene-expression).
41.2 Data
Data used in the preparation of this article were obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies and non-profit organizations, as a $60 million,
5-year public-private partnership. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), positron emission tomography (PET), other
biological markers, and clinical and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s dis-
ease (AD). Determination of sensitive and specific markers of very early AD progression
is intended to aid researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical
Center and University of California-San Francisco. ADNI is the result of efforts of many
co-investigators from a broad range of academic institutions and private corporations,
and subjects have been recruited from over 50 sites across the U.S. and Canada. The
initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-
GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55
to 90, to participate in the research, consisting of cognitively normal older individuals,
people with early or late MCI, and people with early AD. The follow up duration of
each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects
originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2.
For up-to-date information, see www.adni-info.org.
Chapter 2
Approximate score-based testing
with application to multivariate
trait association analysis
2.1 Introduction
The main part of this chapter has been published in Xu and Pan [2015].
To detect genetic associations in genome-wide association studies (GWASs) and
DNA sequencing studies, in addition to the popular univariate minimum P-value (UminP)
test, many multivariate methods have been proposed to improve statistical power.
Several competitive ones are score based, such as the classic score test, a variance-
component score test in kernel machine regression (KMR) [Kwee et al., 2008; Wu et al.,
2010, 2011], an adaptive score test [Lin and Tang, 2011], and an adaptive sum of pow-
ered score (aSPU) test [Pan et al., 2014]. A challenge is how to extend these score-based
tests to more complex models beyond the generalized linear models (GLMs) for inde-
pendent data. There are several reasons to consider more complex mixed-effects models
in genetic association studies. First, even for a single-trait analysis, to properly account
for some complex and hidden relatedness among the study subjects, or more generally
for population structure or population stratification, mixed-effects models have been
proposed as a general and effective approach [e.g., Yu et al., 2011; Zhang et al., 2010;
5
6Zhou and Stephens, 2014]. These mixed-effects models differ from the standard ones in
that a random effect is introduced to induce correlations among all the subjects, thus
requiring some special and fast algorithms for model fitting as implemented in several
recent software packages. These packages do not directly output the score vector. Sec-
ond, there has been increasing interest in association analysis of multiple traits, which
may help gain power and shed light on pleiotropy. In addition, one may encounter corre-
lated traits as arising from familial studies. To account for correlations among multiple
traits, either marginal models (based on generalized estimating equations, GEE) [Liang
and Zeger, 1986] or mixed-effects models [Breslow and Clayton, 1993] can be applied.
For quantitative traits, a linear mixed-effects model (LMM) can be used, from which
the score vector can be derived. Accordingly the KMR test has been extended to LMMs
[Maity et al., 2012; Schifano et al., 2012]. However, it is unclear how to extend the KMR
and other score-based tests to GLM models (GLMMs) and Cox mixed-effects models,
for which there is no closed form for the score vector (because the marginal likelihood
involves an integral with random effects and in general has no closed form) [Breslow
and Clayton, 1993]. Although as an alternative to GLMM, marginal models/GEE can
be used, from which (generalized) score-based tests can be derived [Wang et al., 2013;
Zhang et al., 2014], there may be substantial differences between the two in terms of
modeling assumptions, interpretation, and thus their choices [Diggle et al., 2013]. More
importantly, in genetic association studies, as discussed earlier, random effects may be
necessary to effectively account for population structure, prompting the use of non-
LMMs. In these situations, due to the lack of computer output or closed-form solution
for the score vector, it is challenging to implement score-based tests.
In this chapter, we propose a simple and yet general method to approximate the
score vector for any model. It is based on the asymptotics of an estimator of the param-
eters to be tested. It applies to both the maximum-likelihood estimates (MLEs) and
estimating function-based estimates. Its implementation involves only a few lines of R
code. We demonstrate its use in two types of mixed-effects models, a multivariate LMM
(mvLMM) proposed very recently for genetic association analysis of multiple quantita-
tive traits while correcting for cryptic relatedness and population stratification [Zhou
and Stephens, 2014], and a GLMM with correlated binary traits. Among others, we
use both real and simulated data to illustrate possible power gains of some approximate
7score-based tests over the standard Wald and UminP tests.
2.2 Methods
2.2.1 Review: Some Score-based Tests
Suppose U = (U1, . . . , Uk)
′
is the score vector for a set of k parameters to be tested with
H0 : ψ = 0. The classic score test is
Tsco = U
T Ĉov(U)−1U (2.1)
which is aymptotically equivalent to the Wald test and likehood ratio test (LRT). The
UminP test that has been widely used in GWASs can be writted as
TUminP =
k
max
j=1
U2j /Vjj (2.2)
where Vjj is the jth diagonal element of V = Ĉov(U). Recently, a variance-
component score test in KMR has been proposed for GLMs and shown to be powerful
for analysis of single nucleotide polymorphism (SNP) sets [Kwee et al., 2008; Wu et al.,
2010, 2011]. As discussed by Pan (2011), with a linear kernel it is equivalent to the sum
of squared score (SSU) test:
TSSU = U
TU =
k∑
j=1
U2j . (2.3)
Pan et al. [2014] proposed a family of the so-called SPU tests:
TSPU(γ) =
p∑
j=1
Uγj (2.4)
for a set of integers γ ≥ 1. It is easy to see that SPU(1) and SPU(2) are exactly the same
as the Sum test and the SSU test, respectively [Pan, 2009]; the sum test, an example of
so-called burden tests, has been shown to perform well for genetic association testing,
especially for rare variants, under some situations [Li and Leal, 2008; Pan, 2009]. In
8addition, for an even integer γ →∞, we have
TSPU(γ) ∝
 p∑
j=1
|Uj |γ
1/γ → max
j
|Uj | = TSPU(∞), (2.5)
the SPU(∞) is closely related to the UminP test (but ignoring possibly varying variances
of Uj ’s). Alternatively, an SPU(γ) test can be regarded as a weighted score test [Lin
and Tang, 2011] with adaptive weights Uγ−1j on each component j. In practice, because
it is unknown which γ value would yield high power, we use an adaptive SPU (aSPU)
test to combine the evidence across the SPU tests:
TaSPU = min
γ∈Γ
PSPU(γ) (2.6)
where PSPU(γ) is the P -value of the SPU(γ) test, and Γ contains a set of candidate
values γ. Pan et al. [2014] found that in many situations Γ = 1, 2, 3, . . . , 8, ∞
appeared to perform well, which will be used here.
In general, resampling methods can be used to obtain P-values for the SPU and aSPU
tests. In this chapter, we assume that the asymptotic null distribution of the score vector
U ∼ N(0, V ) holds (under H0). Accordingly, we can generate B-independent copies of
the null score vector U (b), for which the B copies of the SPU test statistics can be calcu-
lated. Then the P -value of each SPU(γ) is calculated as PSPU(γ) =
∑B
b=1 I(|T (b)SPU(γ)| ≥
|TSPU(γ)|)/B. Furthermore, based on the same B copies of the simuated score vectors,
we calculate the P -value for the aSPU test as PaSPU =
∑B
b=1 I(T
(b)
aSPU ≤ TaSPU)/B with
T
(b)
aSPU = minγ∈Γ p
(b)
γ and p
(b1)
γ =
∑
b6=b1 I(|T
(b)
SPU(γ)| ≥ |T
(b1)
SPU(γ)|)/(B − 1).
In this chapter, we use the SPU and aSPU tests as examples, though other score-
based tests [e.g., Lin and Tang, 2011; Sun et al., 2013; Wu et al., 2010] can be equally
applied. Our main point does not depend on the choice of a specific score-based test;
rather, we aim to show how to extend a score-based test to cases where there is no
easy access to the score vector, as arising in below two important applications. To be
concrete, we focus on detecting genetic association with SNPs, but the proposed method
is generally applicable to other problems of interest.
92.2.2 Two Examples Models
First we need some notations, which will be used in the rest of the article unless specified
otherwise.
Suppose we observe for each individual i = 1, . . . , n, the response vector Yi =
(Yi1, . . . , Yik)
T consists of k traits (Yi is a scalar if k = 1), or in familial data, we
observe for each family i = 1, . . . , n, the vector Yi = (Yi1, . . . , Yik)
T is the response for
the k members in ith family; Yij (j = 1, . . . , k) can be either quantitative or binary;
Wi = (Wi1, . . . ,Wiq)
T is a vector including q covariates; and genetic scores for a set of
p SNPs Xi = (Xi1, . . . , Xip), where Xij ∈ {0, 1, 2}, ∀j = 1, . . . , p; X is a n × p design
matrix with ith row corresponding to XTi and W is a n × q design matrix with ith
row of W corresponds to W Ti . We emphasize that Xi and Wi can be either common
or different across phenotypes Yi1, . . . , Yik, for example, in familial data, we assume Xi
and Wi to be different for different family members, while in the case where we observe
each individual has multiple traits, we often assume Xi and Wi to be the same for an
individual. In the remainder of the manuscript, unless specified otherwise, we assume
the case where we observe each individual has multiple traits and let the covariates Wi
and Xi be common to phenotypes.
Multivariate linear mixed model
A multivariate linear mixed model (mvLMM) was proposed by Zhou and Stephens
[2014] to test for association with multiple phenotypes while correcting for possible
population stratification. Specifically, suppose we would like to test for association
between a multivariate trait and a single SNP. We first combine the n trait vectors
Y Ti = (Yi1, . . . , Yik) by row such that the resulting response matrix Y is of dimension
n × k, and the jth column of Y corresponds to phenotype j while the ith row of Y
corresponds to the multiple traits from the ith subject; W is an n × q design matrix
for covariates (including a column of 1s for the intercept); x = (x1, ..., xn)
T is an n× 1
vector of genotype scores (i.e., the counts of the minor allele) for the SNP.
The mvLMM can be written as
Y = Wλ+ xψT +G+ E,G ∼MNn×k(0,K, Vg), E ∼MNn×k(0, In×n, V), (2.7)
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where λ is a q× k matrix of regression coefficients for covariates; ψ is a k× 1 vector
of the SNP effect sizes for the k phenotypes; G is an n × k matrix of random effects;
E is an n × k matrix of random errors; K is an n × n known kinship matrix, or more
generally, a genetic relatedness matrix (GRM) estimated from whole-genome genotype
data; In×n is an n×n identity matrix; Vg is a k×k symmetric matrix of genetic variance
components; V is a k×k symmetric matrix of environmental variance components; and
MNnk(0, V1, V2) denotes the n × k matrix normal distribution with mean 0, a column
covariance matrix V1 of dimension n× n, and a row covariance matrix V2 of dimension
k × k. The goal is to test H0 : ψ = 0.
A mvLMM differs from a standard LMM in that an n×n matrix K is used to account
for possible genetic relatedness among all the subjects. Because the kinship matrix K
may be full and may not be block diagonal, it means that all the subjects may be pos-
sibly correlated. However, as discussed by Zhou and Stephen [2014], the mvLMM can
be rewritten more like a standard LMM in the following way. An eigendecomposition of
the relatedness matrix K can be performed as K = UkDkU
T
k , where Uk is a n×n matrix
of eigenvectors and Dk is a diagonal n×n matrix with diagonal elements corresponding
to eigenvalues (i.e., diag(δ1, . . . , δn)). Then one can obtain the transformed phenotype
matrix Y = UkY , transformed covariate matrix W = UkW , transformed SNP vector
x˜ = Ukx, transformed random effect matrix G˜ = UkG, and transformed residual error
matrix G˜ = UkE . After transformation, for each individual i, the transformed pheno-
types given the transformed covariates and SNP follow independent (but not identical)
multivariate normal distributions:
y˜i = λ
T w˜i + ψx˜i + g˜i + e˜i; g˜i ∼MVN(0, δiVg), e˜i ∼MVN(0, Ve), (2.8)
where for i = 1, . . . , n, y˜i
T is ith row vector of Y˜ , w˜i
T is ith row vector of W˜ , x˜i is
ith element of vector x˜, g˜i
T is ith row vector of G˜ and e˜i
T is ith row vector of E˜;
V ar(Y˜i) = δiVg + Ve ≡ Vi.
Based on model (2.8), one can write down the score vector:
U =
n∑
i=1
(W˜i, X˜i)
TV −1i,0 (y˜i − λˆT0 w˜i), (2.9)
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where λˆ0 and Vˆi,0 are obtained by fitting the null model under H0 : y˜i = λ
T w˜i+ g˜i+ e˜i .
It is quite challenging to develop a fast algorithm to fit a mvLMM. Now such an al-
gorithm is implemented in software package GEMMA [Zhou and Stephens, 2014]. However,
as for most software packages, one is not able to obtain the score vector directly from
the output. A simple and practical way to obtain the score vector is, as proposed ear-
lier, to approximate it by the MLE and its covariance estimate, both available directly
from the output of GEMMA; accordingly a score-based test can be simply constructed and
applied.
Generalized linear mixed model
In a familial study, we observe that in each family i, subject j has a univariate trait Yij ,
q covariates Wij = (Wij1, . . . ,Wijq)
T and p SNPs Xij = (Xij1, . . . , Xijp)
T .We would like
to test for association between the trait and the SNPs through a GLMM:
g(µij) = W
T
ijλ+X
T
ijψ + bi, bi ∼ N(0, σ2b ), (2.10)
where g() is a link function, µij = E(Yij |Xij ,Wij , bi) is the conditional mean of the trait
for subject j in family i, λ = (λ1, . . . , λq)
T is a q× 1 vector of regression coefficients for
covariates Wij , ψ = (ψ1, . . . , ψp)
T a p×1 vector of regression coefficients for SNP set Xij
, and bi is a random effect inducing correlations among the traits of the subjects from
the same family. The goal is to test H0 : ψ = 0. However, in general, due to the lack of
the closed form for the marginal likelihood, there is no closed-form expression for the
score vector for ψ either [Breslow and Clayton, 1993]. Hence, it is not easy to develop
a score-based test for such a model. Below we propose a new method to approximate
the score vector, based on which it is straightforward to construct a score-based test.
2.2.3 New Method: Approximating the Score Vector
Estimation via Maximum Likelihood
Suppose we would like to test H0 : ψ = ψ0 in the presence of nuisance parameter
λ. Denote θˆ0 = (ψ
T
0 , λˆ
T
0 )
T as the restricted MLE of θ = (ψT , λT )T under H0, while
θˆ = (ψˆT , λˆT )T as the unrestricted MLE of θ = (ψT , λT )T (i.e., under H1). Partition the
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Fisher’s information matrix H accordingly as
H =
(
Hψψ Hψλ
Hλψ Hλλ
)
, H−1 =
(
Hψψ Hψλ
Hλψ Hλλ
)
, (2.11)
Denote the whole score vector for θ as Uθ(θ) = (Uψ(θ)
T , Uλ(θ)
T )T . As shown by
Kent [1982, the equation following (4.1)],
U ≡ Uψ(θ̂0) = (Hψψ)−1(ψˆ − ψ0) + op(1). (2.12)
Because the consistent estimator Ĉov(ψˆ) = H ψˆψˆ , we have
U ≈ Cˆov(ψˆ)−1(ψˆ − ψ0), Ĉov(U) = Ĉov(ψˆ)−1. (2.13)
Thus, we first fit a full model (under H1) to obtain the MLE ψˆ and its covariance
estimate Ĉov(ψˆ), then we can approximate the score vector U and its covariance matrix
accordingly. In this way, we can construct (approximate) score-based tests such as the
score test, the SPU, and aSPU tests. In particular, it is easy to see that the approximate
score-based score test is the same as the Wald test:
UT Ĉov(U)−1U = (ψˆ − ψ0)T Ĉov(ψˆ)−1(ψˆ − ψ0). (2.14)
Estimation via Estimating Functions
For estimating function-based approaches, although a generalized score test [e.g., Boos,
1992; Kent, 1982; Rotnitzky and Jewell, 1990] can be constructed, the popular statis-
tical software may not provide direct output of such (generalized) score vectors. For
easy implementation, it may be useful to approximate the (generalized) score vector by
the parameter estimate and its covariance matrix. Specifically, by treating an unbiased
mean 0 estimating function as a (generalized) score function and by a Taylor expansion,
we still have Equation (2.12). However, Ĉov(ψˆ)M = H
ψˆψˆ is the model-based covari-
ance estimator, which is not consistent unless all working assumptions hold (essentially
assuming that the estimating function is indeed a score function). More generally, a
consistent sandwich estimator Ĉov(ψˆ)S is used. Hence, we can modify the score vector
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approximation as
U ≈ Ĉov(ψˆ)−1M (ψˆ − ψ0),Cov(U) ≈ Ĉov(ψˆ)−1M Ĉov(ψˆ)SĈov(ψˆ)−1M (2.15)
Accordingly, once we obtain the point estimate ψˆ, its model-based covariance estimate
Ĉov(ψˆ)M and its sandwich estimate Ĉov(ψˆ)S , we can obtain an approximation to the
score vector U , based on which we can construct a score-based test. Again it is easy
to verify that the score test based on the approximate score is exactly the same as the
Wald test.
We explored the use of such tests for marginal approaches to GLMMs for correlated
binary data (i.e., GEE) [Liang and Zeger, 1986] (and to Cox regression for correlated
survival data; not shown). Note that in general our proposed approximate score vector
is derived based on an asymptotically normal point estimator, and thus is only asymp-
totically unbiased, while the generalized score vector is simply the estimating function
being used and is often unbiased for finite samples; this difference leads to varying per-
formances of an approximate score-based test and an exact generalized score test [Boos,
1992] for finite samples, though their difference diminishes as the sample size increases,
as to be shown later for GEE.
2.3 Results
2.3.1 Example
About ADNI data
We applied the methods to the ADNI-1 data consisting of 681 non-Hispanic Caucasians
with both genotypic and phenotypic data. The phenotypes were cortical thickness
measures of some regions of interest (ROIs) in the brain; they were cross-sectionally
processed using FreeSurfer by UCSF researchers [Hartig et al., 2012]. We tested on
about 20 SNPs and several multivariate traits as considered in Shen et al. [2010] and
Zhang et al. [2014]. For the purpose of illustration, we only show the results for two
SNPs and four multivariate traits: APOE-4 in gene APOE that is well known to be
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associated with AD, and rs7526034 on chromosome 1 (LOC199897), both were associ-
ated with multiple neuroimaging phenotypes [Shen et al., 2010]; the four multivariate
traits were left and right sides of Par (denoted as LPar and RPar), each with four ROIs
(inferior and superior parietal gyri, supramarginal gyrus, and precuneus), right side of
Front with six ROIs (caudal midfrontal, rostral midfrontal, superior frontal, lateral or-
bitofrontal, medial orbitofrontal gyri, and frontal pole), right side of LatTemp with three
ROIs (inferior temporal, middle temporal, and su- perior temporal gyri). Given a large
number of parameters to be estimated (> k2 with k traits) in a mvLMM, as pointed out
by Zhou and Stephen [2014], only a small to moderate number of phenotypes (∼ 210)
were recommended to be used for a typical sample size for GWAS (i.e., n in thousands).
Hence, with only a moderate sample size n = 681 here, we only considered a few multi-
variate traits containing no more than six univariate traits (otherwise, in addition to the
questionable asymptotics, we also encountered some numerical convergence problems).
Analysis Results
As shown in Table 2.1, for most SNP-multivariate trait pairs, the aSPU test gave sim-
ilar results as those of the classic Wald and Score tests. However, there were a few
differences. Notably, for rs7526034-RLatTemp, the aSPU test gave a more significant
P-value than those of the Wald and Score tests; on the other hand, for APOE-4-RPar,
it was the reverse. Among the SPU tests, SPU(1) usually gave most significant results,
presumably because of the smaller number of univariate traits (k) and the same direc-
tion of the SNP-univariate trait associations. In summary, our results demonstrate the
feasibility of using our proposed method to approximate the score vector for a complex
mvLMM, and accordingly construct the score-based aSPU test, which might be more
powerful in some situations (to be shown in simulations) and thus can be complementary
to the standard Wald and Score tests.
2.3.2 Simulations
Simulation I: mvLMM
To mimic real data, we used the ADNI data to generate multivariate phenotypes ac-
cording to the fitted the mvLMM models (2.7) while using the covariates and SNPs in
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the ADNI data too. Specifically, two SNP-phenotype pairs, rs7526034-RLatTemp and
APOE-4-RPar were chosen; from their corresponding fitted models (2.7), we obtained
the parameter estimates such as λˆ, ψˆ, Vˆg, and Vˆ.Those parameter estimates except ψˆ,
which was either 0 for the null model or was scaled by a factor 1/2 to reduce the effect
size of the SNP for the non-null model (because we were using a nominal significance
level at 0.05), were then used to simulate the phenotypes by model (3). For each simu-
lated dataset, as before, the MLE of ψ and its covariance estimate were obtained from
GEMMA to approximate its score vector so that the SPU and aSPU tests could be applied.
We used B = 1, 000 to calculate their P -values. As a comparison, we also used the Wald
test, Score test, and LRT directly output by GEMMA. Based on 5,000 replicates for
each setup, we obtained the empirical Type I error and power estimates. However, we
note that there were some convergence problems when running GEMMA for about 1%
and 2% of simulated datasets for the two SNP-phenotype pairs, respectively; our results
were based on the remaining ones without any convergence problems.
As shown in Table 2.2, the Type I error rates for both pairs were only slightly
inflated for all the tests except the LRT, which had largely inflated Type I error rates.
The inflation could be due to a large number of parameters to be estimated in an
mvLMM with a moderate sample size.
Because the Type I error rates based on fitting the mvLMM were slightly inflated,
while it was known that there was barely any population stratification in the ADNI data
[Xu et al., 2014], we fitted the corresponding model after treating K = I; however,we
experienced some numerical convergence problems in fitting the mvLMM, likely due to
that the two unstructured covariance matrices Vg and V were not identifiable (after
forcing K = I). Thus we simply used function gls() in R package nlme to fit a cor-
responding marginal linear model with or without top 10 principal components (PCs);
the PCs were extracted using Plink [Purcell et al., 2007] based on almost a half million
SNPs of the 757 subjects in the ADNI data. As shown in Table 2.3, the Type I error
rates were better controlled. Note that because the simulated data were generated with
K 6= I, some slight inflation of a Type I error rate was expected under the incorrect
assumption K = I.
The two SNP-phenotype pairs were chosen partly because in the ADNI data analysis
the aSPU test gave a more significant P -value than those of the Wald and Score tests
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for pair 1, while it was the opposite for pair 2 (Table 2.1). It was confirmed that in the
simulations the aSPU test was indeed slightly more (or less) powerful than the Wald
and Score tests for pair 1 (or pair 2).
Simulation II: LMM
We considered a case with unrelated individuals and multiple quantitative traits similar
to those in Zhang et al. [2014], for which the exact score vector could be derived. We
would compare the performance of an exact score-based test with that of its approx-
imate score-based one. For each subject i = 1, . . . , n, we generated his/her genotype
data as in Pan [2009]. Specifically, for each subject i, we first generated a latent vec-
tor Gi = (Gj1, . . . , Gj,p+1)
′
from a multivariate normal distribution with a first-order
autoregressive (AR-1) covariance structure with parameter ρ = 0.5: Cov(Gis, Git) =
ρ|s−t|. Second, each latent element Gis was dichotomized to 0 or 1 with probability
Prob(Gis = 1) as its minor allele frequency (MAF), randomly drawn from a uniform
distribution. Third, we independently generated another haplotype for subject i, then
combined the two haplotypes to form the genotypes for subject j . In this way, we
obtained the genotypes of all the subjects.
The first SNP was chosen as the causal one with MAF randomly drawn from a
uniform distribution U(0.3, 0.4), while the MAFs of the other SNPs were independently
drawn from U(0.1, 0.5). For each subject i, we simulated k traits Yi = (Yi1, . . . , Yik)
from a linear model:
Yi = λ+ xiψ + i, (2.16)
where λ = (λ1, . . . , λk)
T , ψ = (ψ1, . . . , ψk)
T ; i
iid∼ N(0, σ2R), with σ = 1 and R as
a compound symmetry (CS) correlation matrix with the correlation r = 0.3; xi is the
genotype dosage of the causal SNP. Under H0 we had ψ = 0; under H1 we had ψm 6= 0
for 1 ≤ m ≤ 5 and ψm = 0 for 5 < m ≤ k. The non-zero ψj ’s were simulated from a
uniform distribution U(0.2, 0.3). In this way, under H1, only the first five traits were
associated with the causal SNP, that is, as k = 5, 10, 20, 30, 40, we gradually increased
the number of the nonassociated traits from 0 to 5, 15, 25 and 35.
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The simulated data were fitted by a LMM:
Yij = λj + xiψj + bi + ij , bi ∼ N(0, σ2b ),  ∼ N(0, σ2e), (2.17)
where bi was a normal random effect to model the correlations among multiple traits,
ij was the random error, xi was a scalar corresponding to the genetic score of the SNP
nearest to the causal SNP.
We implemented both the approximate score-based and exact score-based tests. For
an approximate score-based test, we fitted model (2.17) and used the MLE of ψ to
approximate its score vector and its variance-covariance matrix. For an exact score-
based test, we fitted the reduced LMM modeled under H0, Yij = λj + bi + ij , to obtain
the MLEs λˆ = (λˆ1, . . . , λˆk)
T . Denote I as the k × k identity matrix. The exact score
vector and its variance-covariance matrix can be written as
U =
n∑
i=1
(I,Xi)
T Vˆ −1i (Yi − λˆ),Cov(U) =
n∑
i=1
(I,Xi)
T Vˆ −1i (I,Xi), (2.18)
where Vˆi was the MLE of Vi with its diagonal elements σˆ
2
b +σˆ
2
 and off-diagonal elements
σˆ2b . Partition the score vector and its covariance into two parts corresponding to the
interceptand ψ parameters, respectively,
U =
(
U1
U2
)
,Cov(U) =
(
V11 V12
V21 V22
)
, (2.19)
then we have the exact score vector for ψ as U2 and its covariance matrix Cov(U2) =
V22 − V21V −111 V12.
To estimate the Type I error and power, 1, 000 datasets were independently simu-
lated and analyzed. Each of the 1, 000 datasets consisted of 1, 000 subjects. We used
B = 1, 000 to obtain P -values for any permutation based methods. As a comparison,
we also showed the results from the UminP.
As shown in Table 2.4, first, regardless of the test being examined, its version based
on the approximate score vector and that based on the exact score vector gave almost
the same results, suggesting the high accuracy of the asymptotic approximation in this
case. Second, we note that the Type I error rates were satisfactorily controlled, even
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for 40 traits. Third, in agreement with Zhang et al. [2014], the aSPU test was more
powerful than the score test for five traits, but not for other numbers of traits; both
were much more powerful than single trait based UminP test, presumably due to the
former twos combining information across the five associated traits.
Simulation III: GLMM
We considered a familial/trio study design with a single binary trait; because there were
multiple subjects in each family, their traits might be correlated. For each of the two
parents in each family i = 1, . . . , n, we generated their haplotypes and thus genotypes
as described in the previous section (with ρ = 0.8); then their offsprings haplotype and
thus genotype data were obtained according to the Mendelian transmission. In this
way, we obtained the genotype data with p+ 1 SNPs for each subjects. The SNP at the
center (i.e., at position p/2 + 1) was chosen as the causal one with MAF 0.3, while the
MAFs of the other SNPs were independently drawn from U(0.1, 0.4). Figure 1 shows
linkage disequilibrium plots for the generated SNPs (after the causal SNP was removed)
based on one parent from each family.
For subject j in family i, denote xij as the genotypic score for the causal SNP, and
Xij = (Xij1, . . . , Xijp)
T as a vector of the genotypic scores for the p noncausal SNPs.
The disease indicator Yij = 0 or 1 was generated from the below GLMM: Assuming λ0
is the background log odds ratio, ψ0 is the effect sizes, the resulting GLMM model can
be written as
Logit(E[Yij |bi]) = λ0 + xijψ0 + bi, bi ∼ N(0, σ2b ), (2.20)
where λ0 = −log(4) was chosen to have a 20% background disease prevalence, while ψ0
at varying effect sizes was used to investigate the empirical Type I error (ψ0 = log(1))
and power (ψ0 > log(1)). We fixed σb = 1, and considered two cases with (p = 10,
n = 200) and (p = 20, n = 400). For each simulation setup, we generated 1,000
simulated datasets to estimate the empirical Type I error or power.
We fitted both a GLMM (2.10) and a corresponding marginal model to test H0 :
ψ = 0. A GLMM was fitted using function glmer() from R package lme4. Either
the Laplace approximation (LA) or adaptive Gaussian quadrature (AGQ) was used to
approximate the (marginal) log-likelihood. For AGQ, we specified the number of points
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per axis nAGQ = 25; in the manual of lme4, it was mentioned that “a model with a
single, scalar random-effects term could reasonably use up to 25 quadrature points per
scalar integral” [Bates et al., 2014]. For a marginal model, both a working independence
and a working CS correlation structures were used in GEE. We then applied our method
to approximate the score vector for the fitted GLMM and GEE models, respectively,
based on which we applied the SPU and aSPU tests; we used B = 1, 000 to calculate
their P-values. As a comparison, we also showed the results from the UminP and Wald
tests; recall that the Wald test is equivalent to the approximate score test.
As shown in Table 2.5, it seems that the Type I error rates were appropriately
controlled by all the tests except the Wald test, which gave slightly inflated Type I error
rates in GEE as well known in the literature [e.g., Zhang et al., 2014]. It is clear that, for
the same fitted model, the aSPU test was much more powerful than the popular UminP
and Wald tests. Among the SPU tests, the SPU(1) was nearly as powerful as SPU(2)
and SPU(3) for a smaller number of parameters to be tested with p = 10, but it was
less powerful than the latter two for p = 20. This is in agreement with the analysis and
motivation of the SPU tests: for p = 10, because all the 10 SNPs were correlated with
the causal SNP, the SPU(1) test was expected to be powerful, as more generally known
for the burden tests; on the other hand, for p = 20, because some SNPs were barely
correlated with the causal SNP, to minimize the effects on power of the nonassociated
SNPs, a larger γ (here γ = 3) would yield higher power for the SPU(γ) test. Among
the three fitted models, the aSPU test based on GEE(CS) was more powerful than that
based on the other two models, the latter of which gave similar results; the lower power
of GEE(Ind) might be due to the use of the working independence correlation structure,
while the GLMM was fitted by an approximate maximum likelihood (using either the
LA by default, or ACQ in the function glme), leading to loss of efficiency. It is noted
that the results from the LA and ACQ approximations were very close; they seemed to
be a little conservative with Type I rates much lower than the nominal 0.05.
Because the proposed method of approximating the score vector is asymptotic, to
further evaluate its finite-sample performance, we also applied the score-based tests
based on the exact, not approximate, GEE (generalized) score formulas, as implemented
in Zhang et al. [2014]. Comparing the test results in Tables 2.5 and 2.6, we can see that
the approximate score-based tests had slight losses of power for the smaller sample size
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n = 200, but performed equally well as the exact score-based tests for the larger sample
size n = 400.
2.4 Conclusions
We have described an asymptotic approach to approximating the score vector in some
complex models, such as a mvLMM or GLMM. The approximate score vector can then
be used to construct any score-based tests, including KMR and aSPU tests for multiple
traits or familial data. Using both real and simulated data, we have demonstrated such
approximate score-based tests can improve power over (and control the Type I error
rate better than) the standard Wald test and the UminP test that has been widely used
in GWAS. The proposed approximate score vector offers a simple and general way to
extend many score-based tests to other complex models, in which the score vector is
unavailable from the statistical package being used. Although we have focused on the
mvLMM and GLMM, we also considered the LMM, the Cox frailty model [Therneau
et al., 2003], and the Cox mixed-effects model [Therneau, 2012], and reached similar
conclusions (results not shown to save space); the difference between the two Cox models
is that the latter includes a random effect to account for genetic relatedness across all
subjects, similar to that adopted in the mvLMM. We envision the use of the proposed
approximate score vector in other models.
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Table 2.1: P-values of the various mvLMM-based tests in analysis of the ADNI data.
SNP Test LPar(4) RFront(6) RLatTemp(3) RPar(4)
APOE-4 SPU(1) 1.2×10−5 2.0×10−7 2.0×10−5 1.3×10−6
SPU(2) 8.3×10−2 2.4×10−2 1.3×10−1 3.8×10−4
SPU(3) 1.9×10−1 2.4×10−3 1.9×10−2 1.3×10−2
SPU(4) 1.6×10−1 7.7×10−3 6.8×10−2 1.1×10−3
SPU(5) 3.6×10−1 4.3×10−3 3.5×10−2 2.1×10−2
SPU(∞) 2.9×10−1 5.2×10−3 4.8×10−2 7.8×10−3
aSPU 3.5×10−5 5.0×10−7 6.0×10−5 3.8×10−6
Wald 1.2×10−5 1.4×10−5 4.6×10−5 6.0×10−8
score 1.8×10−5 2.3×10−5 5.9×10−5 1.4×10−7
rs7526034 SPU(1) 5.7×10−2 9.0×10−4 <1.0×10−7 6.2×10−2
SPU(2) 8.2×10−1 5.7×10−2 2.0×10−1 1.4×10−2
SPU(3) 6.5×10−1 5.8×10−2 6.8×10−2 4.8×10−2
SPU(4) 8.4×10−1 8.3×10−2 2.1×10−1 2.6×10−2
SPU(5) 7.7×10−1 7.5×10−2 1.5×10−1 4.8×10−2
SPU(∞) 8.4×10−1 8.4×10−2 2.7×10−1 4.0×10−2
aSPU 1.3×10−1 2.3×10−3 <1.0×10−7 3.5×10−2
Wald 2.6×10−1 1.4×10−5 2.0×10−6 3.5×10−4
score 2.6×10−1 1.6×10−5 3.1×10−6 4.3×10−4
Table 2.2: Simulation I: empirical Type I error and power for two SNP-phenotype pairs,
rs7526034-RLatTemp (pair 1) and APOE-4-RPar (pair 2), based on fitting mvLMM.
Approximate score vector
SPU(γ)
Pair γ = 1 2 3 4 5 ∞ aSPU Wald Score LRT
1 Type I 0.062 0.067 0.067 0.066 0.069 0.068 0.066 0.067 0.067 0.178
Power 0.722 0.103 0.195 0.112 0.139 0.120 0.621 0.599 0.591 0.604
2 Type I 0.058 0.065 0.063 0.066 0.065 0.067 0.068 0.064 0.058 0.188
Power 0.644 0.389 0.335 0.381 0.336 0.361 0.643 0.689 0.674 0.641
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Table 2.3: Simulation I: empirical Type I error and power for two SNP-phenotype pairs,
rs7526034-RLatTemp (pair 1) and APOE-4-RPar (pair 2) based on fitting marginal
linear models (LMs) with or without the top 10 PCs.
Approximate score
SPU(γ)
Model Pair γ = 1 2 3 4 5 ∞ aSPU Wald
LM, 10 PCs 1 Type I 0.049 0.057 0.063 0.057 0.061 0.058 0.061 0.059
Power 0.742 0.092 0.212 0.117 0.158 0.134 0.648 0.611
2 Type I 0.050 0.052 0.050 0.051 0.048 0.049 0.052 0.052
Power 0.616 0.347 0.306 0.347 0.316 0.339 0.610 0.664
LM, no PCs 1 Type I 0.049 0.059 0.062 0.057 0.061 0.057 0.060 0.057
Power 0.749 0.095 0.214 0.116 0.160 0.136 0.645 0.609
2 Type I 0.052 0.056 0.054 0.057 0.052 0.056 0.054 0.053
Power 0.633 0.360 0.317 0.361 0.327 0.352 0.634 0.683
Table 2.4: Simulation II: empirical type I error rates and power of the approximate
(approx) score- and exact score-based tests when multiple traits were correlated with a
CS structure with correlation r = 0.3.
SPU(γ)
Score vector No. of traits UminP γ = 1 2 3 4 5 ∞ aSPU Score
Type I approx 5 0.041 0.042 0.040 0.048 0.038 0.044 0.043 0.042 0.034
10 0.050 0.051 0.056 0.056 0.057 0.059 0.053 0.052 0.059
20 0.048 0.057 0.046 0.048 0.049 0.047 0.050 0.045 0.047
30 0.048 0.048 0.051 0.050 0.049 0.051 0.050 0.053 0.053
40 0.047 0.052 0.042 0.046 0.048 0.045 0.051 0.042 0.046
exact 5 0.043 0.045 0.034 0.042 0.038 0.043 0.043 0.039 0.034
10 0.052 0.051 0.056 0.057 0.054 0.052 0.050 0.052 0.059
20 0.046 0.053 0.051 0.050 0.049 0.048 0.049 0.046 0.047
30 0.047 0.047 0.053 0.056 0.045 0.053 0.050 0.053 0.053
40 0.051 0.055 0.039 0.047 0.045 0.042 0.049 0.046 0.046
Power approx 5 0.140 0.686 0.139 0.288 0.146 0.188 0.144 0.549 0.435
10 0.324 0.274 0.528 0.341 0.454 0.331 0.324 0.486 0.590
20 0.394 0.097 0.597 0.433 0.544 0.403 0.392 0.512 0.606
30 0.378 0.088 0.581 0.395 0.540 0.399 0.375 0.493 0.570
40 0.364 0.071 0.538 0.416 0.532 0.404 0.368 0.474 0.543
exact 5 0.138 0.685 0.133 0.285 0.141 0.182 0.141 0.543 0.434
10 0.323 0.274 0.536 0.334 0.458 0.315 0.322 0.479 0.588
20 0.384 0.099 0.594 0.426 0.544 0.401 0.397 0.519 0.606
30 0.384 0.080 0.571 0.399 0.543 0.398 0.378 0.500 0.569
40 0.369 0.068 0.534 0.419 0.531 0.410 0.368 0.470 0.542
The first five traits were associated with a causal SNP with effect size βj ∼ U(0.2, 0.3); the SNP nearest to
the causal SNP was tested.
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Table 2.5: Simulation III: empirical Type I error (for OR = 1) and
power (for OR > 1) of the approximate score-based tests with cor-
related binary traits.
SPU(γ)
Model Case OR UminP γ = 1 2 3 4 5 ∞ aSPU Wald
GLMM 1 1 0.018 0.044 0.015 0.016 0.011 0.012 0.014 0.020 0.021
(LA) 1.4 0.078 0.125 0.100 0.105 0.088 0.090 0.074 0.100 0.057
1.8 0.216 0.323 0.296 0.294 0.266 0.257 0.195 0.300 0.141
2.2 0.406 0.514 0.494 0.511 0.461 0.452 0.368 0.470 0.280
2.6 0.580 0.702 0.681 0.680 0.645 0.641 0.568 0.667 0.427
3 0.736 0.825 0.822 0.826 0.799 0.794 0.713 0.807 0.587
2 1 0.028 0.030 0.018 0.024 0.017 0.019 0.024 0.023 0.032
1.4 0.096 0.157 0.116 0.138 0.106 0.108 0.090 0.131 0.067
1.8 0.344 0.424 0.422 0.467 0.425 0.431 0.353 0.414 0.187
2.2 0.677 0.668 0.750 0.776 0.750 0.755 0.667 0.748 0.419
2.6 0.862 0.834 0.897 0.914 0.902 0.904 0.848 0.893 0.666
3 0.950 0.918 0.964 0.969 0.968 0.972 0.938 0.963 0.825
GLMM 1 1 0.015 0.047 0.014 0.011 0.008 0.010 0.011 0.022 0.018
(AGQ) 1.4 0.073 0.118 0.084 0.096 0.085 0.083 0.070 0.092 0.039
1.8 0.198 0.310 0.279 0.281 0.248 0.242 0.187 0.281 0.122
2.2 0.390 0.505 0.472 0.489 0.439 0.431 0.353 0.463 0.255
2.6 0.565 0.688 0.669 0.664 0.624 0.616 0.536 0.654 0.397
3 0.724 0.816 0.817 0.817 0.792 0.783 0.695 0.794 0.557
2 1 0.024 0.029 0.016 0.023 0.016 0.015 0.022 0.024 0.025
1.4 0.085 0.149 0.110 0.133 0.096 0.103 0.083 0.122 0.056
1.8 0.329 0.407 0.408 0.450 0.396 0.415 0.332 0.412 0.166
2.2 0.665 0.667 0.727 0.764 0.730 0.737 0.657 0.744 0.374
2.6 0.851 0.833 0.892 0.910 0.895 0.901 0.834 0.888 0.637
3 0.947 0.916 0.962 0.970 0.968 0.970 0.928 0.958 0.810
GEE 1 1 0.030 0.040 0.024 0.023 0.026 0.024 0.026 0.032 0.057
(Ind) 1.4 0.093 0.134 0.108 0.111 0.100 0.099 0.088 0.116 0.106
1.8 0.215 0.291 0.284 0.288 0.253 0.248 0.202 0.272 0.170
2.2 0.375 0.478 0.459 0.467 0.428 0.422 0.366 0.445 0.308
2.6 0.519 0.625 0.625 0.628 0.596 0.588 0.519 0.603 0.438
3 0.672 0.754 0.755 0.757 0.736 0.729 0.656 0.740 0.558
2 1 0.036 0.037 0.035 0.033 0.032 0.034 0.042 0.033 0.081
1.4 0.113 0.146 0.128 0.149 0.134 0.137 0.110 0.146 0.125
1.8 0.323 0.368 0.368 0.410 0.377 0.394 0.320 0.385 0.229
2.2 0.589 0.593 0.662 0.709 0.677 0.680 0.579 0.672 0.427
2.6 0.775 0.761 0.829 0.847 0.826 0.830 0.770 0.825 0.619
3 0.902 0.865 0.926 0.939 0.932 0.928 0.881 0.925 0.755
GEE 1 1 0.044 0.061 0.041 0.037 0.035 0.035 0.034 0.040 0.065
(CS) 1.4 0.116 0.141 0.133 0.136 0.115 0.117 0.111 0.133 0.104
1.8 0.271 0.366 0.349 0.358 0.323 0.319 0.261 0.337 0.222
2.2 0.459 0.576 0.573 0.577 0.541 0.538 0.459 0.547 0.385
2.6 0.653 0.730 0.734 0.740 0.704 0.698 0.632 0.738 0.526
3 0.800 0.845 0.862 0.862 0.847 0.840 0.780 0.851 0.670
2 1 0.039 0.041 0.032 0.035 0.035 0.038 0.041 0.038 0.070
1.4 0.124 0.183 0.159 0.180 0.151 0.163 0.124 0.167 0.137
1.8 0.433 0.476 0.500 0.543 0.509 0.508 0.438 0.506 0.309
2.2 0.750 0.712 0.805 0.832 0.806 0.809 0.755 0.791 0.544
2.6 0.895 0.881 0.925 0.943 0.933 0.931 0.883 0.925 0.749
3 0.969 0.934 0.971 0.982 0.978 0.978 0.962 0.976 0.881
The two cases were for (n = 200, p = 10) and (n = 400, p = 20). A GLMM was fitted
using either the Laplace (LA) or adaptive Gaussian quadrature (AGQ) approximation;
the working correlation structure in GEE was assumed to be either independent(Ind) or
compound symmetry (CS).
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Table 2.6: Simulation III: empirical Type I error (for OR = 1) and power (for OR
> 1) of the GEE score-based tests with correlated binary traits.
SPU(γ)
Model Case OR UminP γ = 1 2 3 4 5 6 7 8 ∞ aSPU Score
GEE 1 1 0.036 0.047 0.037 0.038 0.031 0.027 0.031 0.033 0.033 0.034 0.038 0.042
(Ind) 1.4 0.090 0.129 0.120 0.117 0.108 0.106 0.099 0.097 0.093 0.090 0.117 0.074
1.8 0.228 0.295 0.305 0.303 0.277 0.264 0.254 0.248 0.245 0.220 0.284 0.148
2.2 0.404 0.474 0.480 0.489 0.459 0.450 0.433 0.428 0.425 0.399 0.462 0.280
2.6 0.567 0.630 0.654 0.658 0.623 0.614 0.603 0.591 0.577 0.555 0.625 0.406
3 0.698 0.766 0.786 0.779 0.759 0.752 0.740 0.736 0.727 0.694 0.765 0.544
2 1 0.049 0.046 0.044 0.038 0.039 0.042 0.045 0.044 0.044 0.048 0.051 0.054
1.4 0.124 0.141 0.152 0.158 0.148 0.151 0.137 0.134 0.125 0.115 0.153 0.092
1.8 0.355 0.369 0.403 0.429 0.413 0.415 0.392 0.385 0.368 0.344 0.413 0.198
2.2 0.627 0.595 0.690 0.725 0.696 0.699 0.672 0.669 0.658 0.613 0.693 0.399
2.6 0.803 0.770 0.852 0.865 0.843 0.841 0.827 0.825 0.820 0.787 0.841 0.597
3 0.915 0.875 0.941 0.949 0.941 0.942 0.933 0.930 0.924 0.895 0.934 0.745
GEE 1 1 0.040 0.066 0.047 0.048 0.044 0.043 0.042 0.041 0.041 0.043 0.050 0.041
(CS) 1.4 0.119 0.140 0.135 0.134 0.127 0.122 0.120 0.116 0.114 0.114 0.130 0.082
1.8 0.282 0.361 0.370 0.369 0.342 0.329 0.315 0.308 0.300 0.276 0.349 0.192
2.2 0.487 0.572 0.582 0.585 0.554 0.546 0.533 0.525 0.510 0.474 0.554 0.357
2.6 0.651 0.738 0.763 0.747 0.727 0.719 0.700 0.693 0.688 0.647 0.737 0.506
3 0.823 0.847 0.865 0.870 0.850 0.845 0.837 0.834 0.829 0.797 0.865 0.644
2 1 0.047 0.044 0.041 0.040 0.045 0.048 0.038 0.041 0.039 0.044 0.049 0.054
1.4 0.150 0.172 0.162 0.183 0.159 0.168 0.154 0.159 0.149 0.140 0.168 0.098
1.8 0.446 0.465 0.519 0.543 0.527 0.525 0.502 0.502 0.486 0.465 0.512 0.258
2.2 0.766 0.712 0.825 0.832 0.823 0.823 0.805 0.807 0.793 0.770 0.816 0.507
2.6 0.908 0.879 0.928 0.947 0.937 0.942 0.931 0.928 0.922 0.896 0.931 0.739
3 0.973 0.936 0.975 0.982 0.981 0.979 0.979 0.979 0.978 0.967 0.978 0.866
The two cases were for (n = 200, p = 10) and (n = 400, p = 20).
Chapter 3
Binomial mixture model based
association testing to account for
genetic heterogeneity for GWAS
3.1 Introduction
The main part of this chapter has been published in Xu and Pan [2016].
Genome-wide association studies (GWAS) have been extremely successful in iden-
tifying thousands of common genetic variants, mostly single-nucleotide polymorphisms
(SNPs), associated with common disease and complex traits (NHGRI Catalog: http:
//wwww.genome.gov/gwastudies/). Some important discoveries on the genetic archi-
tecture for complex traits are the following. First, genetic heterogeneity is everywhere:
multiple SNPs and risk loci have been identi-fied for many common disease and complex
traits, suggesting the plausibility and even ubiquity of a polygenic model. Second, the
effect sizes of most causal SNPs are estimated to be from moderate to small, many of
which with smaller effect sizes are yet to be identified. Consequently, larger sample sizes
and more powerful statistical tests are always needed in order to identify more risk loci.
However, almost all GWAS have adopted single SNP based analysis without explicitly
accounting for (unknown) genetic heterogeneity, leading to possible loss of power as
convincingly shown in simulation studies [Londono et al., 2012; Qian and Shao, 2013;
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Zhou and Pan, 2009]. Note we consider unknown genetic heterogeneity here, rather than
known phenotype heterogeneity as discussed in Darabi and Humphreys [2011]. Based
on a two-component binomial mixture model of Zhou and Pan [2009], if any given locus
contains a causal SNP, then the patient population is decomposed into two subpopula-
tions: the first subpopulation consists of the patients whose disease is associated with
the disease allele at the locus, whereas the second includes those with disease caused
by other unknown alleles at other unknown risk loci. In addition to contrasting the
allele frequencies (i.e., means or first moments) between the control and case groups as
targeted by the most popular 1 df trend test, the proposed mixture model can capture
some other distributional differences of the allele (i.e., second moments) between the
two groups. For example, in an extreme case, even if there is barely any difference of
the allele frequencies between the two groups, leading to no power of the trend test, if
the mixture model assumption holds, then a mixture model based likelihood ratio test
(LRT-H) may still be able to detect the distributional differences of the allele between
the two groups. Qian and Shao [2013] extended the two-component binomial mixture
model to one with more than two components, for which an LRT-H statistic with a
simple closed-form and an asymptotic null distribution was derived, facilitating its ap-
plication to GWAS. Surprisingly, to our knowledge, it has not yet been applied to any
GWAS. In fact, we are not aware of any other analyses of GWAS that explicitly account
for genetic heterogeneity. Here we review the LRT-H and apply it to the Wellcome Trust
Case Control Consortium (WTCCC) GWAS data. To ensure that our conclusion is not
limited to any specific disease, we considered multiple diseases. We demonstrate that
the LRT-H test can be much more powerful than the popular trend test in identifying
a much larger number of associated SNPs and risk loci.
3.2 Methods
For each subject i, suppose Xi = 0, 1 or 2 is the number of the minor allele of a SNP
to be tested, and Yi = 0 or 1 is the disease indicator. The methods are all based on
single SNP analysis by testing on each SNP individually and separately, hence we can
focus on only one SNP. The goal is to test for possible association between the SNP and
disease.
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3.2.1 The Trend Test and Related Tests
Most of the existing association tests ignore possible genetic heterogeneity due to the
disease. For example, the most popular Cochran-Armitage 1df trend test can be for-
mulated as the Score test in a logistic regression model [Wellek and Ziegler, 2011] (or
more generally a GLM or Cox PHM for other types of traits)
logit(Pr(Yi = 1)) = β0 + β1Xi (3.1)
to test the null hypothesis H0: β1 = 0. It is well known [Clayton et al., 2004] that the
Score test is
TS =
X¯(1) − X¯(0)√
V̂ar(X¯(1) − X¯(0))
,
where X¯(d) is the sample mean of Xi’s with Yi = d for d = 0 or 1. The Score test is
asymptotically equivalent to the Z-test for one SNP (and equivalent to Hotelling’s T 2
test for multiple SNPs [Xiong et al., 2002; Fan and Knapp, 2003]). Specifically, one can
model the conditional distribution of Xi as binomial:
(Xi|Yi = 0) ∼ Bin(2, θ0), (Xi|Yi = 1) ∼ Bin(2, θ∗),
for which we’d like to test the null hypothesis H ′0: θ0 = θ∗, which is equivalent to the
original H0. It is easy to see that, the Wald test for H
′
0 is
TW =
X¯(1) − X¯(0)√
V˜ar(X¯(1) − X¯(0))
,
which differs from TS in the variance estimates used in the denominator, but nonethe-
less is asymptotically equivalent to TS . Furthermore, the asymptotically equivalent
likelihood ratio test (LRT) can be also applied:
TL = 2 log(LHLD)− 2 logL0
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with
LH =
2∏
g=0
B2(g, θˆ0)
mg , LD =
2∏
g=0
B2(g, θˆ1)
ng , L0 =
2∏
g=0
B2(g, θˆ01)
mg+ng ,
where ng and mg are the genotype frequencies as summarized in Table 3.1, the maximum
likelihood estimates (MLEs) of the minor allele frequencies (MAFs) under H0 and H1
are
θˆ01 =
2n2 + 2m2 + n1 +m1
2n+ 2m
, θˆ0 =
2m2 +m1
2m
, θˆ1 =
2n2 + n1
2n
,
and
B2(g, p) = Pr(X = g) =
(
2
g
)
pg(1− p)2−g
is the probability mass function for a binomial distribution X ∼ Bin(2, p).
The above three tests all share the same (asymptotic) null distribution as a chi-
squared distribution χ21 with 1 df.
Rather than using a trend test based on the additive genetic model for Xi, a more
general 2df test can be formulated by fitting an expanded regression model:
logit(Pr(Yi = 1)) = β0 + β1Xi + β2X
2
i , (3.2)
and we test H ′′0 : β1 = β2 = 0 with one of the three asymptotically equivalent Score
test, Wald test and LRT, all with an asymptotically null distribution of χ22 with df=2.
Interestingly, as pointed out by Kim et al. [2010], β2 measures the difference of Hardy-
Weinberg coefficients in the disease and control groups, hence a 2df test can be regarded
as testing on both allele frequency difference and Hardy-Weinberg coefficient difference
between the two groups. In this chapter, we used R function glm() to fit a logistic
regression model and applied the Wald test.
3.2.2 Hardy-Weinberg Equilibrium (HWE) Exact test
A Hardy-Weinberg Equilibrium (HWE) test can be applied to the case group (with
notation shown in Table 3.1) for association analysis [Nielsen et al., 1998]. Given that
the total number of observed minor allele is na = 2n2 + n1, under the assumption of
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HWE, the probability of observing n1 heterozygotes:
P (N1 = n1|n, na) = 2
n1n!
n2!n1!n0!
× na!(2n− na)!
(2n)!
, (3.3)
and the p-value is calculated as
PHWE =
∑
n∗1
I[P (N1 = n1|n, na) ≥ P (N1 = n∗1|n, na)]× P (N1 = n∗1|n, na). (3.4)
We conducted the HWE exact test of Wigginton et al. [2005] as implemented in function
hwexact() from R package hwde.
3.2.3 Association Testing under Genetic Heterogeneity
To fully and explicitly account for genetic heterogeneity, Zhou and Pan (2009) proposed
a binomial mixture model for the disease group while using a usual binomial model for
the control group:
(Xi|Yi = 0) ∼ Bin(2, θ0), (Xi|Yi = 1) ∼ piBin(2, θ) + (1− pi)Bin(2, θ0), (3.5)
where θ0 is the background MAF for the controls. In contrast, for the case group, we
assume θ is the probability of having the minor allele on a chromosome for a subpopula-
tion of cases with disease caused by (or associated with) the minor allele, while for other
subpopulations of cases the disease is caused by (unknown) variants at other unlinked
loci, and thus for them the probability of having the minor allele at the locus of interest
is the same as that for the controls. We test H0 : θ = θ0 or pi = 0. Zhou and Pan
[2009] considered more general scenarios with different θ0’s for cases and controls, or
with more than one non-null component for cases, but recommended the above two-
component mixture model due to the non-identifiability issues with the more general
models.
There are several important implications from the mixture model. First, the mixture
model differs from the usual (implicit) assumption of (X∗i |Yi = 1) ∼ Bin(2, θ∗) with
θ∗ = piθ + (1 − pi)θ0 for cases. Although E(X) = E(X∗), it is shown [Zhou and Pan,
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2009] that
E(X2i |Yi = 1)− E(X∗2i |Yi = 1) = pi(1− pi)(θ − θ0)2 ≥ 0,
where the strict inequality holds for the non-degenerated case with θ∗ 6= θ0, pi 6= 0 and
pi 6= 1. Hence, the binomial mixture model introduces an overdispersion of the minor
allele as compared to a binomial distribution with the same MAF. While the most
popular 1df trend test compares the mean difference of the genotype scores between
the control and case groups, it ignores the possible genetic heterogeneity in the case
group and thus possible differences in high moments of the genotype scores between the
two groups. Hence, taking advantage of the existing genetic heterogeneity (as modeled
by the mixture model), an association test can gain power in detecting differences in
both the means (i.e. first moments) and higher-order moments (e.g. second moments)
between the control and case groups, which is closely related to the expanded regression
model (3.2). Second, as shown by Zhou and Pan [2010], the mixture model also implies
that HWE is violated in the case group under genetic heterogeneity, suggesting its
connection to the HWE test.
Since complex diseases can be caused by a large number of genetic variants, it may
be desirable to use a mixture model with more than two components to capture the
complex heterogeneity. Qian and Shao [2013] extended the two-component mixture
model to a more general form for the disease group as follows:
(Xi|Yi = 1) ∼
J∑
j=1
pijBin(2, θj), (3.6)
with J ≥ 2, 0 < θj < 1 and pij ≥ 0 for any j = 1, ..., J , and
∑J
j=1 pij = 1. Note that
J ≥ 2 is unknown and does not need to be specified.
To test the null hypothesis H0: θ1 = θ2 = · · · = θJ (or pij = 1 and pik = 0 ∀k 6= j),
Qian and Shao [2013] developed a likelihood ratio test under genetic heterogeneity
(LRT-H). The likelihoods LH and L0 are the same as before except
LD =

∏2
g=0B2(g, θˆ1)
ng , if 4n0n2 ≤ n21;∏2
g=0(ng/n)
ng , if 4n0n2 > n
2
1.
(3.7)
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Under H0, the LRT-H statistic TLRT-H = 2 log(LDLH)−2 logL0 asymptotically follows a
mixture of two chi-squared distributions with 1 and 2 dfs respectively, i.e. 0.5χ21 +0.5χ
2
2.
Note that since the model (3.5) is not equivalent to the model (3.6), the asymptotic null
distribution of the LRT-H statistics for the two models may be different.
3.3 Application to the WTCCC data
3.3.1 Quality Control
We applied the methods to the Wellcome Trust Case Control Consortium (WTCCC)
data [Burton et al., 2007]. The data include two control groups, called the National
UK Blood Services (NBS) and 1958 British Birth Cohort (58C). To illustrate that a
conclusion is not limited to a specific disease, we considered four traits: Bipolar disorder
(BD), coronary artery disease (CAD), Crohn’s disease (CD), and type 2 diabetes (T2D).
We followed the quality control procedures of Burton et al. [2007] to screen for
subjects and SNPs. In addition, we removed any SNP with a p-value < 5.7 × 10−7 by
the LRT-H test contrasting the two control groups (58C vs NBS) or (NBS vs 58C); the
same cutoff 5.7×10−7 was used by Burton et al. [2007] for the HWE test applied to the
combined control group to remove SNPs. After QC, the genotyping rates were greater
than 99.9% for all the four datasets (each with a combined case and control sample).
The numbers of subjects in the control group (i.e. NBS+58C) before and after QC were
3,004 and 2,938 respectively. The numbers of autosomal SNPs and subjects for each
disease group before and after QC are summarized as in Table 3.2.
3.3.2 GWAS Results
A genome-wide scan was conducted for each dataset with each of the four tests applied
to each SNP. The corresponding Q-Q plots are shown in Figure 3.2, confirming no
obvious population structures, as supported by the estimated inflation factors all close
to 1 (Table 3.3).
After identifying significant SNPs at the usual genome-wide significance level of
5 × 10−8, we applied the method of Psychiatric Genomics Consortium [PGC, 2014] to
define LD-independent (index) SNPs and risk loci. Briefly, first, among all significant
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SNPs, an SNP is defined to be an LD-independent SNP if it is in weak LD with r2 < 0.1
with a more significant SNP within a 0.5Mb window; second, a risk locus is defined as
a basepair (BP) interval including all the SNPs with r2 > 0.6 to an LD-independent
SNP, and any two risk loci within the distance of 0.25Mb are merged.
The numbers of significant SNPs and risk loci identified by each test are shown
in Figures 3.3 and 3.4. It is clear that HWE test identified the largest numbers of
significant SNPs and risk loci, most of which overlapped with those of the LRT-H test;
this can be explained by the close connection between the two tests: a binomial mixture
model implies the Hardy-Weinberg disequilibrium. Second, by the close relationship
between the binomial mixture model and the expanded regression model (3.2), most of
the significant SNPs and risk loci identified by the 2df test were also uncovered by the
LRT-H test. Third, perhaps most importantly, since the LRT-H test also contrasts the
allele frequency differences between the case and control groups as does the 1df trend
test, the significant SNPs and risk loci identified by the popular trend test were almost
all recovered by the LRT-H test. Finally, the LRT-H test also discovered some unique
significant SNPs and risk loci.
Some example SNPs identified to be significant by LRT-H, but not by other tests,
are shown in Table 3.4. Some significant risk loci identified by the LRT-H or HWE test,
but not by the other two tests, are confirmed to be within 0.25 Mb of some previously
identified SNPs or risk loci, as shown in Table 3.5. The LocusZoom plots [Pruim et al.,
2010] for the significant risk loci uniquely identified by LRT-H are shown in Figures 3.5
- 3.8. To facilitate interpretation, we also added their predicted GenoCanyon scores [Lu
et al., 2015]; a higher score predicts a higher likelihood for one or more SNPs in the
nearby region to be functional. As GenoCanyon only supports hg19 while the original
WTCCC data were all based on hg18, we lifted the annotation for the WTCCC data to
hg19 using the UCSC web interface (http://genome.ucsc.edu/cgi-bin/hgLiftOver)
before generating LocusZoom and GenoCanyon plots. We can see that many of the
significant risk loci are in the regions with high functional scores.
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3.4 Conclusions
We have shown possible power gain of the proposed LRT-H test which is closely related
to the Hardy-Weinberg equilibrium (HWE) test. Briefly speaking, when applied to the
WTCCC GWAS data, we found that the HWE test on the case group could identify the
largest number of associated SNPs and risk loci for each of the four diseases considered,
most of which overlapped with those of LRT-H, though LRT-H could uniquely detect
some risk loci too. Although the HWE test has long been proposed as a possible
choice for association testing [Nielsen et al., 1998; Wittke-Thompson et al., 2005], it has
seldom been used and “often under-exploited” [Balding, 2006] for such a purpose but
most widely used only for SNP genotyping quality control. It is likely that some of the
significant SNPs identified by the HWE test and LRT-H are due to genotyping errors,
but some may be true positives. A challenge is to validate and interpret them as for
any new discovery in GWAS.
Table 3.1: The genotype frequencies for case-control data of a SNP.
AA Aa aa Total
Case n0 n1 n2 n
Control m0 m1 m2 m
Table 3.2: The QC summary. For each disease study group, both case and two control groups
are included. The number of subjects for the two control groups (i.e. NBS+58C) were before
and after QC were 3,004 and 2,938, respectively.
CD BD CAD T2D
Before QC # of Subjects 2,005 1,998 1,988 1,999
After QC # of Subjects 1,748 1,868 1,926 1,924
# of SNPs 356,589 356,011 355,881 356,075
Table 3.3: The inflation factors of various tests.
CD BD CAD T2D
1 df GLM 1.11 1.12 1.07 1.08
2 df GLM 1.09 1.10 1.07 1.07
LRT-H 1.13 1.13 1.09 1.10
HWE 0.96 0.97 0.98 0.97
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Table 3.4: Example SNPs which are identified to be significant by LRT-H, but not by
HWE, 1 df Trend or 2 df Genotypic test.
Disease SNP CHR BP LRT-H 1 df Trend 2 df Genotypic HWE
CD rs6677092 1 238239905 1.35e-08 2.50e-04 9.51e-07 4.45e-06
BD rs5754321 22 31600461 1.49e-08 5.31e-03 4.51e-03 2.47e-07
CAD rs326296 3 97643917 6.28e-11 1.40e-05 2.39e-06 4.87e-07
T2D rs9300013 11 32461118 4.62e-08 7.16e-03 2.58e-02 6.35e-07
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Table 3.6: Simulation: empirical Type I error and power when the number of inde-
pendent columns (denote as “No. ind”) is 25, 35, and 65. “RV.asy” and “RV.perm”
standards for asympototic and permutation-based RV test, respectively.
SPC(γ)
No. Ind γ = 1 2 3 4 5 6 7 8 ∞ aSPC RV.asy RV.perm
25 Type I 0.045 0.065 0.015 0.035 0.020 0.020 0.025 0.035 0.035 0.035 0.060 0.070
Power 0.38 0.85 0.86 0.95 0.91 0.95 0.91 0.87 0.56 0.96 0.86 0.85
45 Type I 0.040 0.050 0.045 0.030 0.035 0.035 0.035 0.040 0.060 0.020 0.055 0.055
Power 0.16 0.52 0.57 0.76 0.72 0.76 0.65 0.69 0.37 0.71 0.52 0.52
65 Type I 0.055 0.050 0.045 0.045 0.035 0.045 0.050 0.065 0.050 0.055 0.065 0.065
Power 0.11 0.42 0.34 0.53 0.46 0.61 0.47 0.51 0.29 0.52 0.42 0.31
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Figure 3.1: Linkage disequilibrium plots for simulated genotypes with (n = 200, p = 10)
(left panel) and (n = 400, p = 20) (right panel).
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Figure 3.2: Q-Q plots of various tests for CD (first row), BD (2nd row), CAD (3rd row) and
T2D (bottom row).
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Figure 3.3: Venn-diagrams of the significant SNPs at the genome-wide significance level of
5×10−8 identified by each test for traits CD, BD, CAD and T2D (from the top to the bottom).
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Figure 3.4: Venn-diagrams of the significant risk loci identified by each test for traits CD, BD,
CAD and T2D (from the top to the bottom).
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Figure 3.5: LocusZoom plots of the risk loci for trait CD, uniquely identified by LRT-H. The
GenoCanyon scores for the LD-independent (index) SNPs are 2.71e-05, 5.3e-04, 1.00, 2.4e-03
and 5.5e-03 respectively.
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Figure 3.6: LocusZoom plots of the risk loci for trait BD, uniquely identified by LRT-H. The
GenoCanyon scores for the LD-independent (index) SNPs are 0.999, 0.888 and 0.972 respectively.
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Figure 3.7: LocusZoom plots of the risk loci for trait CAD, uniquely identified by LRT-H . The
GenoCanyon scores for the LD-independent (index) SNPs are 3.35e-06 and 1.24e-06 respectively.
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Figure 3.8: LocusZoom plot of the risk locus for trait T2D, uniquely identified by LRT-H. The
GenoCanyon score for the LD-independent (index) SNP is 5.34e-05.
Chapter 4
Adaptive testing for association
between two random vectors in
moderate to high dimensions
4.1 Introduction
To investigate genetic control of gene expression, it is common and useful to conduct
association analysis between single nucleotide polymorphisms (SNPs) and gene expres-
sion (i.e. mRNA or transcript) levels, also known as eQTL analysis. This often involves
massive univariate testing. For example, Colantuoni et al. (2011) examined 30,176 ex-
pression probes and 625,439 SNPs, leading to 1.89×1010 (19 billion) possible SNP-gene
associations. After the Bonferroni adjustment, 1,628 individual associations surpassed
the genome-wide significance level. However, when they conducted a global test for
possible association between all SNPs and all transcripts, no association was detected.
“This dramatic lack of association between genetic distance and transcriptome distance
across our sample is a surprising result that requires further interrogation. It is possible
that no association is found in Fig. 4 because most of the genetic polymorphisms mea-
sured do not impact on gene expression.” We agree with Colantuoni et al. (2011) on the
possible reason for the lack of a global association in the presence of some individual
associations: it is due to the lack of power of a global test for high-dimensional data
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with only sparse signals. Furthermore, the authors also commented on that, surpris-
ingly, no association was found even for smaller subsets of the SNPs and genes. We note
that their used method was Mantel’s (1967) test, which was originally proposed for low-
dimensional data and may have limited powewr for moderate- to high-dimensional data
as to be confirmed. Nevertheless, this example pinpoints the importance of conducting
global association testing with high-dimensional data, given that most of the existing
tests are almost exclusively developed for low-dimensional data for historical reasons,
as reviewed in Josse and Holmes (2014).
Some commonly used tests for association between two random vectors include the
RV test (Escoufier, 1970), the Mantel test (Mantel, 1967) and the dCov test (Sze´kely et
al., 2007). The RV test is based on the RV coefficient as a multivariate generalization
of Pearson’s correlation coefficient. It is perhaps the most popular one in many fields,
especially in ecology. The Mantel test aims to detect a possible correlation between two
distance matrices among the subjects based on the two random vectors respectively; it is
noted that the Mantel test was used by Colantuoni et al. (2011). The dCov test has only
become popular recently due to its attracting property of being consistent in detecting
any possible associations, including non-linear and non-monotonic relationships. A
common problem with the above tests is their treating all the variables in the two
random vectors equally a priori, which is perhaps reasonable for low-dimensional data,
but not for moderate- to high-dimensional data: as for the SNP-gene expression data
of Colantuoni et al. (2011), most of the SNPs do not have regulatory function; even for
those regulatory ones, their targets are likely only a few, not most, of the genes. That
is, for high-dimensional data, we expect that many or even most (e.g. SNP-gene) pairs
are not associated, which is ignored by the above existing tests, leading to their noise
accumulations and thus substantial power loss as to be confirmed in later numerical
studies. Hence, to boost power, it is important to conduct variable selection or variable
weighting. With weak associations, it is difficult for accurate variable selection, so
we take a variable weighting approach. In our approach, we use the data to adaptively
determine a weight for each pair of the variables: if a pair is more likely to be associated,
we assign a higher weight to it. This will effectively down-weight many of those non-
associated pairs, alleviating the effects of noise accumulation hindering most existing
tests for high-dimensional data. Our adaptive test can be regarded as a generalization
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of the RV test to high-dimensional data, as to be shown later.
We note that the above tests aim to tackle the same problem as association testing
for multiple traits or longitudinal traits in genetics (e.g., Maity et al 2012; He et al 2015;
Fan et al 2016; Wang et al 2013, 2015, 2017; Kim et al 2016 and references therein),
but the two lines of research seem to be largely non-overlapping; it is also our goal here
to bridge the gap between the two lines of research. In particular, our proposed test is
related to another adaptive test called GEE-aSPU, originally designed in genetics for
testing for multi-trait and multi-SNP associations in low to moderate dimensions (Kim
et al., 2016), but we will also show some computational advantages of the proposed test
over GEE-aSPU. It is also connected with kernel machine regression and kernel distance
methods (Hua and Ghosh, 2015). Furthermore, due to the simplicity of our proposed
test, it can be also extended to detect non-linear or even non-monotonic associations
by borrowing the idea from the dCov test, though our test is much more powerful than
the dCov test for sparse signals in moderate- to high-dimensions.
The rest of the article is organized as follows. In section 2 we will briefly review
the RV test, which serves to motivate our proposed aSPC test. We then outline the
connections of the aSPC test to some existing tests before presenting its several gener-
alizations. Section 3 applies the new and some existing tests to an SNP-gene expression
data drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), highlighting
some advantages of the new tests over some existing ones. In section 4 more simulation
results are shown to support the power and flexibility of the aSPC test. We end with a
summary of the main conclusions in section 5.
4.2 Methods
Our goal is to test for association between two random vectors xp×1 and yq×1 in p and
q dimensions respectively. We have n iid observations on x-y pair as stored in two
matrices Xn×p and Yn×q, respectively; each row of the two matrices corresponds to an
observed x-y pair. Denote X·l as the lth (l = 1, . . . , p) column of matrix X and Y.m) as
the mth (m = 1 . . . q) column of Y . It is assumed throughout that each column of the
two matrices is centered at mean 0 with a unit variance(or Euclidean norm). We will
use X and Y to test for association between x and y; with some abuse of notation, we
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also call association between X and Y .
4.2.1 Review: the RV test
The two cross-product matrices of X and Y are WX = XX
T and WY = Y Y
T , both of
which are of size n×n. To measure their proximity, the Hilbert-Schmidt inner product
between matrices WX and WY can be used:
< WX ,WY >= tr(XX
TY Y T ) =
p∑
l=1
q∑
m=1
Cov2n(X.l, Y.m), (4.1)
where Covn(X·l, Y.m) is the sample covariance between columns X·l and Y.m. The RV
coefficient, a correlation coefficient proposed by Escoufier (1973) for two random vectors,
is computed by normalizing the Hilbert-Schmidt inner product by the matrix norms:
RV(X,Y ) =
< WX ,WY >
||WX ||||WY || =
tr(XXTY Y T )√
tr(XXT )2tr(Y Y T )2
, (4.2)
which accounts for possibly different scales of x and y. The population RV coefficient
is ρ(x,y) = tr(ΣxyΣyx)/
√
tr(Σ2xx)tr(Σ
2
yy), where Σxy is the population covariance
between x and y. Our goal is to test H0 : ρ(x,y) = 0.
If each column of X and of Y is standardized to have a zero mean and a unit
variance, as always assumed here, the RV coefficient can be simplified as:
RV(X,Y ) =
tr(XXTY Y T )
pq
=
∑p
l=1
∑q
m=1 corr
2
n(X.l, Y.m)
pq
∝
p∑
l=1
q∑
m=1
corr2n(X.l, Y.m),
(4.3)
where corrn(X·l, Y.m) is the sample Pearson correlation coefficient between columns X·l
and Y.m.
A permutation method can be used to calculate the P -value. Specifically, for each
permutation b = 1, . . . , B, we permute the rows of matrix X (or Y ), then calculate the
corresponding RV coefficient RV(b); the P -value is calculated as the sample proportion
(
∑B
n=1 I(RV ≤ RV (b)) + 1)/(B + 1).
47
4.2.2 New method: an adaptive sum of powered correlation (aSPC)
test
To generalize the RV coefficient as reformulated in equation (4.3), we propose a family
of so-called sum of powered correlation (SPC) tests:
SPC(γ) =
p∑
l=1
q∑
m=1
corrγn(X.l, Y.m) (4.4)
for a set of integers γ ≥ 1. Each term corrγn(X.l, Y.m) in equation (4.4) can be re-written
as corrγn(X.l, Y.m) = wlmcorrn(X.l, Y.m), where wlm = corr
γ−1
n (X.l, Y.m) is regarded as a
weight for corrn(X.l, Y.m). Therefore, a larger |corrn(X.l, Y.m)| will a yield higher weight
|wlm|, which will help improve power with sparse alternatives that are common for
moderate- to high-dimensional data. Specifically, when γ = 1, all corrn(X.l, Y.m)’s will
be assigned an equal weight 1, which will be beneficial for dense alternatives (i.e. if all or
most of the columns of the two matrices X and Y are associated); however, when γ ≥ 2,
the larger the γ, the higher weights would be assigned to those larger corrn(X.l, Y.m)’s,
more and more favoring sparse alternatives (i.e. when only few of the columns of X and
Y , as indicated by those larger corrn(X.l, Y.m)’s, are truly associated with each other).
In the extreme case of a sparse alternative with only one or few associated column-pairs
between X and Y , for an even integer γ →∞, we have
SPC(γ) ∝
(
p∑
l=1
q∑
m=1
corrγn(X.l, Y.m)
)1/γ
→ max
j
|corrn(X.l, Y.m)| = SPC(∞), (4.5)
which we can see largely eliminates the effects of non-associated pairs and thus is ex-
pected to be more powerful for more sparse alternatives. We emphasize that, with large
p and q in moderate to high dimensions, noise accumulation is a severe problem for
sparse alternatives, which explains power loss of many non-adaptive tests like the RV
test, as to be shown later.
In summary, depending on the type of a true alternative hypothesis to be tested,
i.e. dense or sparse, a small or a large γ would yield higher power for the SPU(γ)
test. In practice, because it is unknown what is the true alternative and thus which γ
value would yield high power, we develop an adaptive SPC (aSPC) test to combine the
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evidence across the SPC tests:
aSPC = min
γ∈Γ
PSPC(γ) (4.6)
where PSPC(γ) is the P -value of the SPC(γ) test, and Γ contains a set of candidate
values for γ. In general, Γ = {1, 2, . . . , γu,∞} with 1 < γu < ∞ can be used; larger
p and q require a larger γu; a practical guideline on the choice of γu is that SPC(γu)
gives results similar to SPC(∞). We used Γ = {1, . . . , 8,∞} throughout this paper for
its good performance based on our limited experience.
A permutation method can be used to obtain the P -values of all the SPC and
aSPC tests in a single loop (or layer) of permutations. Briefly, B copies of the null
statistic SPC(γ)(b) for each γ ∈ Γ and b = 1, . . . , B can be calculated by permuting
the rows of matrices X (or Y ) B times. The P -value of each SPC(γ) is calculated
as PSPC(γ) = (
∑B
b=1 I(|SPC(γ)(b)| ≥ |SPC(γ)|) + 1)/B. Furthermore, based on the
same B copies of the null statistics, we calculate the P -value for the aSPU test as
PaSPC = (
∑B
b=1 I(aSPC
(b) ≤ aSPC) + 1)/(B + 1) with aSPC(b) = minγ∈Γ p(b)γ and
p
(b1)
γ = (
∑
b 6=b1 I(|SPC(γ)(b)| ≥ |SPC(γ)|)(b1) + 1)/B.
4.2.3 Connections with some existing tests
We start by establishing a relationship between the aSPC test (with the Pearson corre-
lation coefficient) and an existing test called GEE-aSPU, which was proposed by Kim et
al. (2016) for multiple trait-multiple SNP associations. We first review the GEE-aSPU
test before pointing out its connection to the aSPC test.
First we need some notations. Denote Xi· = (xi1, . . . , xip) and Yi· = (yi1, . . . , yiq)T
as ith row in matrices X and transpose of ith row in Y for i = 1, . . . , n, respectively;
denote Xi = I ⊗Xi·, where I is a q× q identity matrix, and ⊗ represents the Kronecker
product.
Suppose we treat each column Y·m for m = 1, . . . , q in Yn×q as a response, each
column X·l for l = 1, . . . , p in Xn×p as a covariate or predictor of interest; recall that
Y·m and X·l has been standardized to have zero mean and unit variance. We can then
test if there is any association between the columns of X and those of Y with a marginal
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generalized linear model
g(E(Yi·|Xi)) = Xiβ, (4.7)
where g(.) is a canonical link function, and β is a pq-dimensional vector of unknown
parameters of interest. We aim to test the null hypothesis H0 : β = 0. Denote Y¯ as
the mean vector of columns of Y , which is a zero vector of length q. With a canonical
link function and a working independence model in GEE (Liang and Zeger, 1986), the
generalized score vector for β is
U =
n∑
i=1
XTi (Yi· − Y¯ ) =
n∑
i=1
XTi Yi·. (4.8)
It is easy to verify U = (U11, . . . , Up1, . . . , U1q, . . . , Upq)
Twith Ulm = X
T
·l Y·m = corrn(X·l, Y·m).
That is, each element Ulm measures the association between columns X·l and Y·m. The
GEE-SPU test statistic is defined by
SPU(γ1, γ2) =
q∑
m=1
( p∑
l=1
Uγ1lm
) 1
γ1
γ2 = q∑
m=1
( p∑
l=1
corrγ1n (X·l, Y·m)
) 1
γ1
γ2 . (4.9)
Denote Γ1 and Γ2 are two sets of positive integers. The GEE-aSPU test statistic is then
defined as the minimum p-value of SPU(γ1, γ2)’ tests for all γ1 ∈ Γ1 and γ2 ∈ Γ2:
aSPU = min
γ1,γ2
pγ1,γ2 (4.10)
Here we observe a close connection between the SPC test and the GEE-SPU test:
if γ1 = γ2 = γ, we have SPU(γ, γ) = SPC(γ). The difference between aSPC and aSPU
tests is that the latter searches for two optimal (γ1, γ2) in a two-dimensional space (i.e.
over Γ1 × Γ2), while aSPC searches over only a one-dimensional space (i.e. Γ); the
GEE-aSPU test reduces to aSPC if we impose γ1 = γ2 = γ.
Due to the currently inefficient implementation of the GEE-aSPU test (for its general
regression framework) in R package GEE-aSPU, it cannot be applied to high-dimensional
data: it requires too much memory space for its inefficient storage of the design matrix
with dimension np × pq (or nq × pq) if Y (or X) is treated as the response. As an
example, the GEE-aSPU test will need about 40Gb of memory if p = q = 300 and
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sample size n = 200, not yet affordable by many computers. In contrast, due to its
simplicity, the aSPC test is applicable to high-dimensional data.
Finally, we comment on that the SPC(2) test is also closely related to several other
tests, further illustrating the potential power of the aSPC test. First, since the dCov test
and the Hilbert-Schmidt independence criterion (HSIC) test are equivalent (Sejdinovic
et al., 2013), Hua and Ghosh (2015) called them kernel distance covariance method
(KDC); they further established the equivalence of KDC and multivariate kernel ma-
chine regression (KMR) test (Maity et al., 2012) (if the same kernels are used in the
two). On the other hand, Kim et al. (2016) pointed out that GEE-SPU(2,2) is similar
to multivariate KMR with a linear kernel; the two are exactly the same if the true
correlation matrix is used as the working correlation structure in GEE for the former,
which in general does not hold (unless the columns of Y are independent), because the
working independence model is used in GEE-SPU tests. Now, by the equivalence be-
tween SPC(2) and GEE-aSPU(2,2) and by the above results, we see the close similarity
between SPC(2) and other tests. Using the weighting argument motivating the devel-
opment of other SPC(γ) tests with γ > 2, we expect that the other tests (i.e. dCov,
HSIC and KMR with linear kernels) may lose power with sparse association patterns,
which is to be confirmed in our later simulations.
4.2.4 Extensions
So far we define an SPC test with the Pearson correlation coefficients between the
columns of the two matrices. Here we generalize the SPC and thus aSPC tests with
several other dependence measures and with covariates.
Fisher’s transformation
We may take Fisher’s z-transformation on the sample Pearson correlation coefficient
rlm = corrn(X.l, Y.m) before plugging into equation (4.4). The reason is to account
for heterogeneous variances of the sample correlations for an alternative hypothesis;
as to be shown next, the variance of a sample correlation increases monotonically
as the absolute value of the true correlation decreases (under the normality assump-
tion). Specifically, the sample correlation rlm = corrn(X.l, Y.m) is replaced by zlm =
1
2 ln ((1 + rlm)/(1− rlm)) in equation (4.4). Under the normality assumption (on each
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pair of the columns of X and Y ), zlm is approximately normally distributed with mean
1
2 ln((1 + ρlm)/(1− ρlm)) and a constant variance 1/(n− 3), where ρlm is the population
Pearson correlation coefficient.
Given that zlm∼˙N(12 ln((1 +ρlm)/(1−ρlm)), 1/(n−3)), it is not hard to find the ap-
proximate distribution of the sample Pearson correlation coefficient is rlm∼˙N(ρlm, (1−
ρ2lm)
2/(n − 3)); the variance (1 − ρ2lm)2/(n − 3) is obtained by the delta method and
clearly confirms the monotonicity mentioned above. In particular, since the variance is
largest for no correlations, not taking Fisher’s transformation or not stabilizing the vari-
ance may lead to loss of power, especially for high-dimensional data, for which sparse
alternatives are expected with many non-associated pairs.
Whenever needed, to distinguish using Fisher’s z-transformed Pearson correlation
coefficients from using other dependence measures for the SPC and aSPC tests, we will
use SPC.P and aSPC.P to refer to the former:
SPC.P(γ) =
p∑
l=1
q∑
m=1
zγlm, (4.11)
and the aSPC.P test is similarly defined as before.
The aSPC test with Spearman’s correlation
More generally, the sample Pearson correlation coefficient term rlm = corrn(X.l, Y.m)
in equation (4.4) can be replaced by a different dependence measure. For example,
we can use Spearman’s (1904) rank correlation coefficient, which is effective for mono-
tonic relationships, in contrast to only linear relationships by Pearson’s coefficient. The
Spearman correlation coefficient is defined as the Pearson correlation coefficient between
the ranked variables. Specifically, X·l and Y·m (l = 1, . . . , p and m = 1, . . . , q) are con-
verted to the rank score vectors rank(X·l) and rank(Y·m) (e.g. rank score = 1 for the
smallest value in X·l (or Y·m) and rank score = n for the largest value in X·l or (Y·m)).
The sample Spearman correlation coefficient is calculated as
rlm(Spearman) =
Covn(rank(X·l), rank(Y·m))√
Covn(rank(X·l), rank(X·l))Covn(rank(Y·m), rank(Y·m))
, (4.12)
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where Covn(u, v) is a sample covariance between vectors un×1 and vn×1. Then the SPC
statistic with Spearman’s rank correlation coefficient is defined as:
TSPC.Sp(γ) =
p∑
l=1
q∑
m=1
rγlm(Spearman), (4.13)
and aSPC.Sp is defined similarly as before.
The aSPC test with the distance correlation
Another extension is to replace each sample Pearson correlation coefficient in equation
(4.4) by a corresponding distance correlation coefficient (dCor), which is derived based
on the distance covariance (dCov) (Szykely et al., 2007) and is consistent in detecting
any dependency, not only the linear ones (detectable by Pearson’s) or monotonic ones
(by Spearman’s); for example, in the presence of non-linear (and non-monotonic) de-
pendency, use of dCor is expected to be more powerful, as to be confirmed in our later
simulations. We first review the usual dCov test and then modify the SPC test with
the distance correlations.
The standard dCov test utilizes all columns in X and Y to calculate the pairwise
distance before computing the sample distance covariance:
aij = ||Xi· −Xj·||t, bij = ||Yi· − Yj·||t, (4.14)
where || · || denotes the Euclidean distance/norm; Xi· and Yi· denote the ith row of X
and Y respectively (i = 1, . . . , n); t ∈ (0, 2] and t = 1 corresponds to the Euclidean
norm, which was used in our data analysis throughout unless specified otherwise. The
pairwise distances are doubly centered:
Aij = aij − a¯i· − a¯·j + a¯··, Bij = bij − b¯i· − b¯·j + b¯··, (4.15)
where a¯i·, a¯·j and a¯·· are the ith row mean, the jth column mean and the grand mean of
matrix [aij ]; b¯i·, b¯·j and b¯·· are similar defined for matrix [bij ]. Then the squared sample
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distance covariance of X and Y is defined as:
dCov2n(X,Y ) =
1
n2
n∑
i,j=1
AijBij . (4.16)
A permutation method can be used to calculate the P -value. The null statistics T
(b)
dCov =
1
n2
∑n
i,j=1A
(b)
ij B
(b)
ij can be calculated based on each permuted sample X
(b) and Y (b),
where X(b) (or Y (b)) is generated by permuting the rows of X (or Y ). The P -value is
calculated as PdCov = (
∑B
b I(dCov
(b) ≥ dCov) + 1)/(B + 1) based on B permutations.
In the standard dCov test, all columns of X and Y are used to calculate the pairwise
distances; that is, each variable (or dimension) is treated equally a priori, which may
not be a good idea for high-dimensional data for the abundance of sparse alternatives.
In contrast, in our SPC test, each column/variable of X and Y is treated differently ac-
cording to the magnitudes of their estimated pairwise associations. Specifically, similar
to the standard dCov test, first we define all pairwise distances among the observations
based on the ith and jth elements of X·l and Y·m as
aij(l) = ||Xil −Xjl||t, bij(m) = ||Yim − Yjm||t, (4.17)
which computes the n × n distance matrices (aij(l)) and (bij(m)) for i = 1, . . . , n, j =
1, . . . , n, l = 1, . . . , p and m = 1, . . . , q. Denote a¯i·(l), a¯·j(l) and a¯··(l) as the ith row mean,
the jth column mean and the grand mean of [aij(l)]; similarly, denote b¯i·(m), b¯·j(m) and
b¯··(m) for [bij(m)]. The elements aij(l) and bij(m) are then doubly centered as:
Aij(l) = aij(l) − a¯i·(l) − a¯·j(l) + a¯··(l), Bij(m) = bij(m) − b¯i·(m) − b¯·j(m) + b¯··(m), (4.18)
then the squared sample distance covariance is defined as:
dCov2n(X·l, Y·m) =
1
n2
n∑
i,j=1
Aij(l)Bij(m). (4.19)
The sample distance correlation (dCor) between X·l and Y·m is then defined as
dCorn(X·l, Y·m) =
dCovn(X·l, Y·m)√
dCovn(X·l, X·l)dCovn(Y·m, Y·m)
. (4.20)
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The SPC.dCor test statistic is defined as:
SPC.dCor(γ) =
p∑
l=1
q∑
m=1
dCorγn(X·l, Y·m) (4.21)
and the aSPC.dCor is similarly defined as before.
As to be shown later in simulations, the aSPC.dCor test was much more powerful
than the standard distance covariance (dCov) test for sparse alternatives in even only
moderate dimensions, presumably because the former’s weighting on the pairwise dCor’s
alleviates the harmful effects of noise accumulations in the latter.
The aSPC test with covariates
The aSPC test can be applied to situations with covariates. We only need to first regress
X and/or Y on the covariates, then use the residuals to construct the SPC tests. We
will illustrate such an application in the example section.
4.2.5 Software
The asymptotic- and permutation-based RV tests are available as functions coeffRV()
and RV.rtest() in R packages FactoMineR and ade4, respectively. The permutation-
based Mantel test, dCov test and GEE-aSPU test are in functions mantel(), dcov.test(),
GEEaSPUset() in R packages vegan, energy and GEEaSPU, respectively. We imple-
mented various versions of the new SPC and aSPC tests in an R package aSPC, which
is available on github (and CRAN).
4.3 Real data application
4.3.1 Testing for SNP-gene expression associations
To understand gene regulation, it is important to detect genetic variants like Single
Nucleotide Polymorphisms (SNPs) that are associated with gene expression (i.e. tran-
script) levels, called eQTL (Minas et al., 2013). Due to the relatively small sample size
and a severe penalty on multiple testing for a large number of SNP-gene pairs, it is often
55
low-powered to detect many associations at the individual apir level. As an alternative,
we may first test the association between a set of SNPs and a set of the genes.
The ADNI genotype data consist of 757 subjects from ADNI-1, two hundred and
thirty six of whom also have genome-wide gene expression data based on the whole
blood. A pathway for Alzheimer’s disease (hsa05010, http://www.genome.jp/dbget-bin/
www_bget?hsa05010) was downloaded from Kyoto Encyclopedia of Genes and Genomes
(KEGG) website (Kanehisa et al., 2016). Since the ADNI-1 genotype data are based
on the human genome version hg18, we used the hg18 gene coordinate file downloaded
from the PLINK website (http://pngu.mgh.harvard.edu/~purcell/plink/) to iden-
tify the starting base pair (bp) and ending bp for each gene. We then extracted two
sets of the SNPs for the genes in the AD pathway. In the first, the SNPs within each
gene were selected, including possibly both protein coding and regulatory SNPs; in the
second, to focus on only regulatory SNPs, only the SNPs within the upstream 20kb of a
gene’s starting bp or within the downstream 20kb of its ending bp were selected. Since
the results were similar, we will discuss only the first dataset.
To account for possible effects of age and gender on gene expression, we used a linear
regression model to regress each gene’s expression level on the two covariates, then used
the residuals as the gene’s adjusted expression levels in the subsequent analysis. In the
end, there were 441 probes corresponding to 151 genes, and 2,483 SNPs (after excluding
those with a minor allele frequency less than 0.05) in the first dataset.
To demonstrate the effects of association patterns, especially the signal sparsity
levels, on the testing results, we screened the SNP-gene pairs using each pair’s P-value
for their marginal association, which was based on a simple linear regression of each
gene’s adjusted expression level on each SNP in the set. The expression level of each
gene was calculated as the average of its corresponding probes for those genes with more
than one probe. We used various threshold values to select subsets of the SNP-gene
pairs, with a marginal P-value smaller than a given threshold. Then we pooled the
SNPs and the probes in the genes surviving such a screening into a SNP set and a
probe set respectively, then tested their associations using various methods. For any
permutation-based test, we used a permutation number B = 1 × 104 (unless specified
otherwise). As the dimensions of the probes and the SNPs were high (i.e. in hundreds
to thousands), it would be infeasible to run the GEE-aSPU test as it required a too
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large memory space. The results are summarized in Table 4.1.
We have the following observations. First, when we included all the SNPs and
the probes (with a P-value threshold 1), the aSPC tests (i.e. aSPC.P, aSPC.Sp, and
aSPC.dCor) all gave significant P-values; in contrast, none of the other tests, including
the RV test, the Mantel test and dCov test, gave any significant P-value less than
the nominal level 0.05. Second, most strikingly, regardless of the dimensions (p, q)
with various threshold values, the aSPC tests consistently gave small and significant
P-values (e.g. < 0.001), showing their robustness to the varying association patterns
(e.g. signal sparsity levels); in contrast, as fewer and fewer, but more significant, SNPs
and probes were included, other global tests gradually gave more and more significant
P-values, suggesting their loss of power in the presence of sparse signals due to their
none-adaptiveness. Third, among the SPC tests, those SPC.P(γ) tests with larger γ
(e.g. γ >= 4) gave more significant P-values than those with smaller γ (e.g. γ < 4),
indicating sparse signals as expected (i.e. most SNP-probe pairs were not associated).
4.4 Simulations
4.4.1 Simulation I: linear associations
To further investigate the operating characteristics of the proposed tests, we compare
their power performance with several existing tests. We first consider the ideal situation
with a linear association between two sets of normal variates.
To generate a simulated dataset, two matrices Xn×p and Yn×p were simulated with
n = 500. First, for each X and Y , p (= 25 ,45 or 65) independent columns were
simulated from a standard multivariate normal distribution. Second, a matrix Zn×10
with ten columns were simulated from a multivariate normal distribution with mean
0 and a compound symmetry covariance matrix (with all diagonal elements equal to 1
and all off-diagonal elements equal to 0.1); for power comparisons, we added the first 5
columns of Z to X and the last 5 columns of Z to Y .
We applied the aSPC.P, aSPC.Sp, aSPC.dCor, RV, Mantel and dCov tests to each
simulated dataset, and and compared their empirical Type I error and power estimates.
The Mantel and dCov tests were conducted with the Euclidean distance. We set B =
1000 for any permutation-based tests. To save computing time, the empirical Type I
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error rates and power of aSPC.dCor were based on 1,000 replicates while for all other
tests, they were based on 10,000 replicates.
As shown in Table 4.2, first, the Type I error rates were in general well controlled
for each test. Second, among all the tests, GEE-aSPU was most powerful, followed
by aSPC.P. Note that, due to the linear association, aSPC.P is expected to be more
powerful than aSPC.Sp (and aSPC.dCor). Third, SPC.P(2) gave the results essentially
the same as both the asymptotic and permutation-based RV tests, as expected. Fourth,
due to the presence many independent columns in the two matrices X and Y , a SPC.P
test with a larger and finite γ (e.g. γ = 6) was more powerful than that with a small
γ ≤ 4; their power difference increased with the number of independent columns. Fifth,
aSPC.dCor gave much higher power than dCov test, due to that SPC.dCor(γ) with
larger γ reduced the effects of noise accumulation with independent columns. Moreover,
we note the extremely low power of the Mantel test, followed by MANOVA.
To assess the computing time and feasibility for the permutation-based RV, GEE-
aSPU and aSPC tests, we changed the number of columns in X and Y to 30, 50, 70 and
100 respectively, and with a sample size n = 200. We then calculated the computing
time with a permutation number B = 1× 103. Note that, for example, for p = q = 300,
GEE-aSPU needs to construct a large design matrix with dimension 60, 000 × 90, 000,
requiring about 40GB of memory. The computing time was based on one processor
(Intel Haswell E5-2680v3 with 2.5GB of memory on Unix system) from a cluster at the
Minnesota Supercomputing Institute (MSI).
As shown in Figure 4.1, first, our implementation of aSPC.P completely in R was
even faster than the RV.perm test, which was surprising given that aSPC.P involved
conducting SPC.P(γ) for γ = 1, . . . , 8,∞ and RV.perm is equivalent to SPC.P(2). Sec-
ond, aSPC.dCor was more computing-intensive than other tests; for data matrices Xn×p
and Yn×q, aSPC.dCor required calculating pairwise distance covariances pq times based
on p + q distance matrices, even if we used more memory space to save the distance
matrices in our current implementation in R.
4.4.2 Simulation II: non-linear associations
Now we consider a more challenging case with a non-linear and non-monotonic associ-
ation. Our simulation set-up was similar to that of Sze´kely et al. (2007).
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Data matrix Xn×5 was simulated from a multivariate standard normal distribu-
tion. To calculate the empirical type I error rates, for each replicate a matrix Yn×5
was simulated from a multivariate standard normal distribution. For power, Yn×p was
generated such that each of the first p0 (p0 = 1, 2, 3, 4 or 5) columns Yij = log(X
2
ij)
for j = 1, . . . , p0 and i = 1 . . . n; when p0 ≤ 4, each of the other columns of Yn×p was
independently and identically simulated from a standard normal distribution. We were
interested in how the empirical power changed as the number of non-linearly associated
column pairs (p0) between X and Y varied from 1 to 5. Six tests were applied, including
aSPC.dCor, aSPC.Sp, aSPC.P, permutation-based RV test, the Mantel test with the
Euclidean distance and Pearson correlation, and dCov. One thousand datasets were
simulated to calculate the empirical type I error and power. We used B = 1000 for
any permutation-based tests. The simulation results are summarized in the left panel
of Figure 4.2 with sample size n = 40.
First, the type I error rates were well controlled for all tests. Second, our aSPC.dCor
test gave much higher power than the usual dCov test. For example, with only one truly
associated pair, the power of aSPC.dCor was 86.5%, much higher than 12.0% of the dCov
test. Third, due to the underlying non-monotonic true associations, as expected, none
of the RV, aSPC.P, aSPC.Sp and Mantel tests performed well.
To further explore the performance of the tests with increasingly sparse associations,
in addition to the above set-up with p0 = 5, we added 75, 115, 195, 295 or 395 inde-
pendent columns to matrix Y , each of which was simulated from a standard normal
distribution. The power curves are shown in the right panel of Figure 4.2. It is clear
that the power of aSPC.dCor remained significantly higher than that of the dCov test,
whereas all other tests had no power.
4.5 Conclusions
We have proposed an adaptive and powerful association test called aSPC for two
moderate- to high-dimensional random vectors. It has been shown to be more powerful
in a a variety of simulations than several commonly used tests. In an application to
a real genotype-gene expression dataset, under various moderately high dimensions for
the SNPs and genes, the proposed test robustly and consistently gave more significant
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P-values than other existing tests, which appeared to lose power dramatically for larger
sets of the SNPs and genes. The proposed aSPC test can be regarded as a generalization
of the standard RV test from low-dimensional data to moderate- to high-dimensional
data with the incorporation of data-adaptive weighting on each variable pair. The main
idea is that, for moderate- to high-dimensional data, often there will be many variable
pairs that are not associated; treating these null pairs equally as other truly associated
pairs will simply accumulate noises, leading to substantial power loss as in most other
existing tests like the RV test. Hence, this main idea is related to the GEE-aSPU test
in genetics. Indeed the aSPC test (more precisely, the version denoted aSPC.P with
Pearson’s correlation) is a special case of the GEE-aSPU test. However, due to its sim-
plicity, the aSPC.P test has some computational advantage over the GEE-aSPU test,
which in its currently implementation is not applicable to high-dimensional data. More
importantly, the aSPC.P test can be easily extended by replacing the Pearson correla-
tion coefficient with other coefficient, which may be more suitable for other non-linear
associations. For example, if the distance correlation is used as in aSPC.dCor, it can
detect non-monotonic associations. Compared to the usual dCov (or dCor) test, again
due to its adaptiveness, the aSPC.dCor test is much more powerful for less dense or
sparse signals for high-dimensional data, as shown in our simulations.
Various versions of the aSPC test are implemented in R package aSPC, freely available
at https://github.com/jasonzyx/aSPC.
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Figure 4.1: The computing time of the permutation-based RV, GEE-aSPU, aSPC.P,
aSPC.Sp and aSPC.dCor tests. The left panel shows the computing time of aSPC.dCor
test as compared to that of all the other tests, while the right panel is a zoom-in for all
the tests except aSPC.dCor.
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Figure 4.2: Simulation II results. The left panel: when the number of columns in X
and Y are 5, the empirical type I error and power curves of the tests as the number
of truly non-linearly associated column pairs between X and Y ranges from 0 (type I
error) to 5. Right panel: when the number of non-linearly associated column pairs in
X and Y is fixed at 5, the power curves of the tests as more and more non-associated
columns are added to Y . The nominal significance level is 0.05.
Chapter 5
A powerful framework for
integrating eQTL and GWAS
summary data
5.1 Introduction
In spite of many successes, genome-wide association studies (GWAS) face two major
challenges. The first is its limited statistical power even with tens to hundreds of thou-
sands of individuals in a typical GWAS or mega-GWAS, thus missing many associated
genetic variants, mostly single nucleotide polymorphisms (SNPs), due to the polygenic
effects and small effect sizes. The second is that even for those few identified SNPs, since
they often do not reside in protein-coding regions, it is difficult to interpret their function
and thus biological mechanisms underlying complex traits. A new gene-based associ-
ation test called PrediXcan was recently proposed to integrate GWAS individual-level
data with an eQTL dataset, alleviating the above two problems in boosting statistical
power of GWAS and facilitating biological interpretation of GWAS discoveries (Gama-
zon et al 2015). It was extended to GWAS summary association data (Torres et al 2017).
A similar approach, called transcriptome-wide association study (TWAS), was proposed
by another group for GWAS individual-level and summary data for one or more eQTL
datasets (Gusev et al 2016). They are motivated by the key fact that many genetic
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variants influence complex traits through transcriptional regulation. Focusing on the
genetic component of expression avoids environmental noise influencing gene expression
and complex traits, thus can increase statistical power. In addition, compared to stan-
dard GWAS, treating genes as analysis units reduces the number and thus burden of
multiple tests, again leading to improved power. By applications to common diseases
like T2D and complex traits like BMI, lipids and height, the authors have convincingly
shown the power of integrating GWAS and eQTL data, gaining biological insights into
complex traits. There are more follow-up studies applying TWAS to other diseases. For
example, Gusev et al (2017) identified some new genes associated with schizophrenia;
interestingly, they also confirmed a previous observation that, contrary to usual GWAS
practice, the nearest gene to a GWAS hit often is not the most likely susceptibility gene,
highlighting the critical role of incorporating gene expression to unravel disease mech-
anisms that may not be achieved by GWAS alone. The current standard and popular
view is that PrediXcan and TWAS work because of their predicting or imputing cis
genetic component of expression for a larger set of individuals in GWAS, facilitating the
following expression-trait association testing. Based on this view, some new methods
have been proposed to improve over TWAS by addressing some existing weaknesses in
gene expression prediction (Bhutani et al 2017; Park et al 2017). In spite of its intuition
and usefulness, the current view on PrediXcan and TWAS may not have told the whole
story. Here we offer some new insights into PrediXcan and TWAS with a novel reformu-
lation on their underlying association testing. Our key observation is that PrediXcan
and TWAS share a common weighted association test; the weights on a set of SNPs in a
gene are the cis-effects of the SNPs on gene expression (derived from an eQTL dataset).
In other words, PrediXcan and TWAS put a higher weight on an SNP (eSNP) that is
more strongly associated with the gene’s expression level, in agreement with empirical
evidence that eSNPs are more likely to be associated with complex traits and diseases
(Nicholae et al 2010). This new formulation also points out the connection to existing
weighted association analysis (Roeder et al 2006). More importantly, since the same
association testing methodology in PrediXcan and TWAS suffers from power loss un-
der some common situations, we develop an alternative and more powerful association
test with broader applications. Since there is no uniformly most powerful gene-based
association test, any single non-adaptive test will lose power in some situations; it is
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important to develop and utilize adaptive tests to yield high power (Li and Tseng 2011;
Lee et al 2012; Pan et al 2014). We propose using such an adaptive and powerful test
under a general and rigorous framework of generalized linear models (GLMs), which
can accommodate various types of quantitative, categorical and survival phenotypes
and can adjust for covariates. It is applicable to both individual-level genotypic, phe-
notypic data and GWAS summary statistics. It si flexible to incorporate a single or
multiple sets of weights derived from eQTL data or other data sources.
5.2 Methods
5.2.1 PrediXcan and TWAS
We briefly review PrediXcan and TWAS for GWAS individual-level data before giving
our new formulation. One first builds a prediction model for a gene’s expression level,
called “genetically regulated expression (GReX)”, by using the genotypes around the
gene based on an eQTL dataset. Next, for a GWAS dataset, one uses the prediction
model to predict or “impute” the GReX of the gene using the SNPs around the gene
for each subject in the GWAS dataset. Specifically, for a given gene, suppose that in an
eQTL dataset, Y ∗ and X∗ = (X∗1 , ..., X∗p )′ are the the expression level of and the p SNP
genotype scores (with additive coding) around the gene. A linear model is assumed:
Y ∗ =
∑p
j=1wjX
∗
j + , where wj is the cis-effect of SNP j on gene expression and  is
the noise. Based on the eQTL dataset, one can use a method, e.g. elastic net (Zou and
Hastie 2005) or a Bayesian linear mixed model (Zhou et al 2013) as used in PrediXcan
and TWAS, to obtain the estimates wˆj ’s. Now for a given GWAS dataset, for each
subject i with the genotype scores Xi = (Xi,1, ..., Xi,p)
′ for the gene, the predicted
GReX is ĜReXi =
∑p
j=1 wˆjXi,j . For a trait Yi for subject i in the GWAS dataset, one
simply applies a suitable GLM
g(E(Yi)) = β0 + ĜReXiβc = β0 +
p∑
j=1
wˆjXi,jβc (5.1)
to test for association between the trait and predicted/imputed expression with null
hypothesis H0: βc = 0, where g() is the canonical link function (e.g. the logit and the
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identity functions for binary and quantitative traits respectively), and E(Yi) is the mean
of the trait. One of the asymptotically equivalent Wald, Score and likelihood ratio tests
can be used.
5.2.2 Novel reformulation and extensions
Here we first point out that PrediXcan and TWAS can be regarded as a special case of
general association testing with multiple SNPs in a GLM:
g(E(Yi)) = β0 + β
′Xi = β0 +
p∑
j=1
Xi,jβj . (5.2)
The goal is to test H0 : β = (β1, ..., βp)
′ = 0. It can be verified that both PrediXcan and
TWAS are a weighted Sum test in the above general model (Pan 2009) with weights wˆj
on each SNP j; that is, PrediXcan and TWAS conduct the Sum test on H0 with the
genotype scores Xi,j replaced by the weighted genotype scores wˆjXi,j in GLM (2). This
new interpretation and formulation will facilitate our gaining insights into PrediXcan
and TWAS, including their possible limitations, thus motivating some modifications for
improvement. It offers a direct and intuitive justification for PrediXcan and TWAS: the
two methods perform well due to their over-weighting on expression-associated SNPs
(eSNPs), as supported by empirical evidence that eSNPs are more likely to be associated
with complex traits and disease (Nicholae et al 2010). Obviously, it also suggests their
extensions to other endophenotypes, and to incorporate prior knowledge and other data
sources related to the GWAS trait of interest, such as previous linkage scans (Roeder
et al 2006), though we do not pursue it here. More importantly, since the Sum test can
be derived under the over-simplifying working assumption of β1 = β2 = ... = βp = βc
in (1) and (2) (i.e. all weighted SNPs have an equal effect size and the same effect
direction, which is in general incorrect), we can see possible limitations of the Sum and
thus PrediXcan and TWAS. As discussed in Pan (2009), Pan et al (2014) and others
(Wu et al 2011), the Sum test may lose power if the effect directions of the (weighted)
SNPs are different, or the effect sizes are sparse (i.e. with many 0s). Accordingly, one
may apply other tests, e.g. the sum of squared score (SSU) test that is equivalent to
a variance-component score test as used in kernel machine regression (also known as
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SKAT in rare variant analysis) with a linear kernel and a nonparametric MANOVA (also
called genomic distance-based regression) with the Euclidean distance metric (Wessel
and Schork 2006), which may yield higher power under many situations (Pan 2011;
Schaid 2010a, 2010b).
5.2.3 New method: aSPU
A class of the so-called sum of powered score (SPU) tests cover both the Sum and SSU
tests as special cases. Specifically, we denote the unweighted and weighted score vectors
for β in (1) as
U∗ = (U∗1 , ..., U
∗
p )
′ =
n∑
i=1
X ′i(Yi−µˆ0i ), U = (U1, ..., Up)′ = WU∗ =
n∑
i=1
WX ′i(Yi−µˆ0i ),
where µˆ0i is the fitted mean of Yi underH0 (with β = 0) in (1), andW = Diag(wˆ1, ..., wˆp).
The effects of the weights can be regarded as replacing the unweighted genotype scores
Xi,j by the weighted genotype scores wˆjXi,j in GLM (2). The Sum (i.e. PrediXcan and
TWAS) and SSU tests based on the weighted genotypes are:
TSum =
p∑
j=1
Uj , TSSU = U
TU =
p∑
j=1
U2j .
More generally, for an integer γ ≥ 1, an SPU(γ) test is defined as
TSPU(γ) =
p∑
j=1
Uγj .
It is clear SPU(1)=Sum and SPU(2)=SSU. Furthermore, for an even integer γ → ∞,
we have TSPU(γ) ∝
(∑p
j=1 |Uj |γ
)1/γ → maxj |Uj | = TSPU(∞). The SPU(∞) is closely
related to the minP test (but ignoring possibly varying variances of Uj ’s); often they
performed similarly (Pan 2009).
Since there is no uniformly most powerful test, for a given situation, any non-
adaptive test may or may not be powerful. By using various values of γ, we yield
a class of SPU tests, one of which is expected to be more powerful in any given situ-
ation. For example, the Sum=SPU(1) test treats each SNP equally a priori, yielding
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high power if all the SNPs are associated with the trait with similar effect sizes and the
same association direction. On the other hand, when only a smaller subset of SNPs are
associated with the trait, or their association directions are different, the SSU=SPU(2)
test is often more powerful. As γ increases, SPU(γ) relies more on the SNPs that are
more strongly associated with the trait, and is thus more powerful for more sparse as-
sociation signals (i.e. fewer associated SNPs). In the end, as γ approaches ∞ (as an
even integer), it only considers the most significant SNP.
Since the optimal value of γ is unknown and data-dependent, we propose using an
adaptive SPU (aSPU) test to data-adaptively approximate the most powerful SPU
test among a set of versatile SPU(γ) tests with various values of γ, thus maintaining
high power in a wide range of scenarios. Empirically we have found that using Γ =
{1, 2, 3, . . . , 6,∞} often performs well and thus adopt it; the aSPU test is defined as
TaSPU = min
γ∈Γ
PSPU(γ), (5.3)
where PSPU(γ) is the p-value of the SPU(γ) test.
P-value calculations: Although asymptotic p-values for the SPU(1)=Sum and SPU(2)=SSU
tests can be calculated (Pan 2009) (with possible small-sample adjustments (Lee et al
2012; Chen et al 2015; Wang 2016)), in general, we can use one layer of Monte Carlo
simulations to estimate the p-values for all the SPU and aSPU tests simultaneously (Pan
et al 2014). Specifically, we simulate null score vectors U (b) ∼ N(0, V ) for b = 1, . . . , B,
from its asymptotic null distribution as multivariate normal with mean 0 and covariance
matrix V ; there is a closed form solution for V (Pan et al 2014). Then the null statistics
T
(b)
SPU(γ) can be calculated from the null score vectors U
∗(b) for b = 1, . . . , B, and its
p-value is PSPU(γ) = [
∑B
b=1 I(|T (b)SPU(γ)| ≥ |TSPU(γ)|) + 1]/(B + 1). Then the p-value for
the aSPU test can be calculated as PaSPU = [
∑B
b=1 I(T
(b)
aSPU ≤ TaSPU) + 1]/(B+ 1) with
T
(b)
aSPU = minγ∈Γ p
(b)
γ and p
(b1)
γ = [
∑
b 6=b1 I(|T
(b)
SPU(γ)| ≥ |T
(b1)
SPU(γ)|) + 1]/B.
5.2.4 Association testing with summary statistics
One practical way to increase the sample size is to form large consortia, aiming for
meta analysis of multiple GWAS, for which often only summary statistics for single
SNP-single trait associations, rather than individual-level genotypic and phenotypic
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data, are available (and practically feasible for many cohorts with possibly different
study designs). Hence it is extremely useful to develop methods like TWAS that are
applicable to GWAS summary statistics as well as to GWAS individual-level data. The
aSPU test is easily extended to GWAS summary statistics without individual-level data.
Suppose that Zj = βˆj/SEj is the Z-statistic for association between the GWAS trait and
SNP j, where βˆj is the estimated (marginal and signed) association effect and SEj is its
standard error. We just need to simply redefine U = WZ with Z = (Z1, Z2, ..., Zp)
′, then
proceed as before. We use a reference sample (e.g. the 1000 Genome Project samples) to
estimate linkage disequilibrium (LD) among the SNPs and thus the correlation matrix
for Z and U (Kwak and Pan 2016; Gusev et al 2016).
5.2.5 Association testing with multiple sets of weights
Now we extend the aSPU test to the case with multiple sets of eQTL datasets, or
more generally, multiple sets of weights. This is important because of the existence
of multiple eQTL datasets measured from different populations or different tissues; it
is in general unclear which one is most suitable. After applications with each eQTL
dataset separately, it may gain statistical power and biological insights to combine the
results across multiple eQTL datasets. Suppose we have K sets of weights, W (k) =
Diag(w
(k)
1 , . . . , w
(k)
p ) for k = 1, 2, . . . ,K, each estimated from a separate eQTL dataset
or using a different method for a common eQTL dataset. To avoid the results depending
on the varying scales of the sets of weights, we first standardize the weights to have∑p
j=1 |w(k)j | = 1 for each k. Based on the score vector U∗ (with individual-level data)
or Z-statistics Z (with GWAS summary data) and the weights W (k), we define U (k) =
W (k)U∗ or U (k) = W (k)Z accordingly. As before, for a fixed γ, we first apply SPU(γ)
to U (k) = (U
(k)
1 , ..., U
(k)
p )′, yielding its test statistic TSPU(γ;k) =
∑p
j=1(U
(k)
j )
γ and and
p-value PSPU(γ;k). We then Z-transform each p-value to a Z-statistic z
∗(γ; k) = Φ−1(1−
PSPU(γ;k)/2), where Φ(.) is the CDF of a standard normal distribution. To recover the
sign of each statistic, for an odd γ, we have z(γ; k) = sign(TSPU(γ;k))z
∗(γ; k); for an
even γ or γ = ∞, we use z(γ; k) = sign(TSPU(1;k))z∗(γ; k). We combine the K sets
of weights through combining the K statistics z(γ) = (z(γ; 1), ..., z(γ;K))′ to form an
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omnibus SPU(γ) test:
SPU(γ)-O = [z(γ)− µ0(γ)]′V −1(γ)[z(γ)− µ0(γ)],
where µ0(γ) and V
−1(γ) are the mean vector and covariance matrix of z(γ) under H0,
which can be calculated along with other p-values inside the single layer of simulations.
Then, as usual, we combine the omnibus SPU(γ)-O tests into an omnibus aSPU test:
TaSPU-O = min
γ∈Γ
PSPU(γ)-O,
where PSPU(γ)-O is the p-value of SPU(γ)-O. As before, the p-values of all the SPU(γ)-
O and aSPU-O can be calculated in a single layer of Monte Carlo simulations.
It is easy to verify that SPU(1)-O is equivalent to the omnibus TWAS, denoted
TWAS-O. Again, by combining SPU(1)-O and other SPU(γ)-O tests, we obtain the
adaptive and omnibus aSPU-O test that may be more powerful across a wide range of
scenarios.
5.3 Results
5.3.1 Application to the WTCCC data
We first applied the aSPU test and PrediXcan to the WTCCC individual-level data with
the weights downloaded from the PrediXcan database, demonstrating the equivalence of
the SPU(1) test and PrediXcan, and more importantly, that the aSPU test could identify
more associated genes than PrediXcan in many cases. Specifically, first, following the
same procedure of quality control (Burton et al 2007), we lifted the annotation of the
WTCCC genotype data from hg18 to hg19 via the UCSC browser; second, we imputed
the genotype data via the Michigan Imputation Server with the following specifications:
1000G Phase 1 v3 as the reference panel, SHAPEIT as the phasing algorithm and EUR
(European) as the target population. After imputation, the variants with a minor allele
frequency (MAF) > 0.05, the HWE exact test P -value > 0.05 and R2 > 0.8 were
kept. As Gamazon et al (2015), we kept only the HapMap Phase 2 subset of SNPs.
We considered 7 traits/diseases, bipolar disorder (BD), coronary artery disease (CAD),
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inflammatory bowel disease (CD), rheumatoid arthritis (RA), hypertension (HT), type
1 diabetes (T1D) and type 2 diabetes (T2D). The weights based on the DGN whole
blood expression were downloaded from the PrediXcan database. There were 8917
genes whose expression levels could be predicted by elastic net with a cross-validated
R2 > 0.01; we thus tested on these 8917 genes with a conservative Bonferroni adjustment
with a genome-wide significance level at 0.05/9000 = 5.56× 10−6.
As most of the genes are not expected to be significantly associated with a trait,
we used a step-up procedure to increase the number of simulations when calculating
the p-values of aSPU and aSPU-O in the subsequent data analysis. We started with a
relatively small B = 103, and re-ran the tests with B = 104 for the genes with p-values
< 5 × 10−3; we repeated this process by increasing B to 10 times of its previous value
for the genes with p-values < 5/B) up to B = 1× 107; finally, to be more accurate for
a p-value around the significance cut-off, we re-ran the tests on the genes with p-values
between 10−5 and 10−6 with B = 1× 108.
Here are the main results. First, as shown in Figure 5.3, as expected, PrediXcan
gave essentially the same results (i.e. p-values) as did the SPU(1) test for each of the
seven traits. Hence, we treat the SPU(1) test to be equivalent to PrediXcan. Second,
as shown in Figure 5.4, the aSPU test identified more significant genes than the SPU(1)
test (or equivalently, PrediXcan) for traits CD, BD and T1D (i.e. (10, 3, 38) versus
(8, 2, 29)), while it was the opposite for HT (i.e. 0 versus 1), and they were tied (with
(1, 4, 0)) for CAD, RA and T2D; note the large difference for T1D. Table 5.1 lists the
significant genes identified by the aSPU test but not by the SPU(1) test (and PrediXcan)
at the genome-wide significance level; some of the significant genes were confirmed in
later studies.
5.3.2 Application to the lipid GWAS summary data
We next applied our new methods and TWAS to a 2010 lipid GWAS summary dataset
(∼100,000 samples, Teslovich et al 2010), while using its follow-up with a larger sample
size (∼189,000) for partial validation. To facilitate comparison, we used the three sets
of weights and the 1000 Genomes Project data as the reference sample, all downloaded
from the TWAS database (on Jan 11th, 2017 ). The three sets of weights were based
on three eQTL datasets: microarray gene expression data of peripheral blood from
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1,245 unrelated subjects from the Netherlands Twin Registry (NTR) (Wright et al
2014), microarray expression data of blood from 1,264 subjects from the Young Finns
Study (YFS), and RNA-seq measured in adipose tissue from 563 individuals from the
Metabolic Syndrome in Men study (METSIM); for each pair of gene-eQTL dataset,
we used the set of the optimal weights estimated by TWAS. For each trait, there were
1264, 3555 and 2295 significant cis-heritable genes with weights from the NTR, YFS
and METSIM studies respectively, resulting in a total of 7114 genes being tested; when
combining across three sets of weights, there were 1223 genes being tested. Thus, we
used a conservative Bonferroni adjustment with 0.05/8500 = 5.88×10−6 as the genome-
wide significance level. The GWAS Z-scores were imputed for any missing SNPs using
the IMPG algorithm (Pasaniuc et al 2014).
The new tests identified more associations
We numerically confirmed the equivalence between the SPU(1) test and TWAS (Figure
5.5). Hence, we used the results of the SPU(1) test to represent those of TWAS in the
following. More importantly, the aSPU test could identify a larger number of significant
genes than TWAS in every case across the four traits (HDL, LDL, TC and TG) and
three sets of weights (NTR, YFS and METSIM); the same conclusion holds for the
omnibus aSPU and omnibus TWAS tests (Table 5.2). As a partial validation, a high
proportion of the identified genes covered at least one genome-wide significant SNP in
the 2010 (∼ 100,000 samples and the larger 2013 (∼ 189,000 samples, Global Lipids
Genetics Consortium 2013).
Compared to TWAS, the aSPU test can still maintain high power if many of the
SNPs in a gene are not associated with a trait. For example, for trait HDL and gene
DR1 with the YFS-based weights, among the 17 SNPs with non-zero weights, there were
only one SNP with a p-value less than 5 × 10−7, resulting in a non-significant p-value
( = 1.4 × 10−4) by TWAS, or equivalently by SPU(1). Since an SPU(γ) test with a
larger γ > 1 relied more on the SNPs with the smaller p-values (i.e. more strongly
associated with the trait), it yielded a more significant p-value with a larger γ: the
SPU(2) and SPU(5) tests gave p-value = 2.9×10−6 and 3.5×10−6 respectively, leading
to the significant p-value = 2.3×10−6 of aSPU in the end. As shown in Figures 5.6-5.7,
since the SPU(1) might not be the most powerful for a given gene, the aSPU test could
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gain statistical power through more powerful other SPU tests like SPU(2).
The new tests identified new associations
Finally, we applied the aSPU and TWAS (and their omnibus versions) to the larger
2013 lipid dataset (Global Lipids Genetics Consortium 2013), listing the numbers of the
significant genes identified by each method in Table 5.3. Again the aSPU test identified
a much larger number of significant associations. The Manhattan plots for the pooled
results of aSPU for each set of the weights and of aSPU-O combining the three sets of
the weights for each trait are shown in Figures 1-2; a comparison between aSPU/aSPU-
O versus TWAS/TWAS-O for trait LDL is shown in Figures 5.8-5.9. In total, aSPU
and TWAS identified 17 and 14 new associations not overlapping with known risk loci
respectively; among the 6 new associations uniquely identified by aSPU test, gene PFAS
was reported to be associated with LDL in a later meta-analysis (Below et al 2016).
The new associations identified by aSPU or/and TWAS are listed in Table 5.4 It is
noteworthy that in Table 4, with the p-values close to the significance cut-off, the aSPU
test barely missed the three significant genes uniquely identified by the SPU(1) test
(i.e. TWAS); in contrast, the SPU(1) test gave the much larger p-values for several
significant genes uniquely identified by aSPU.
It was shown previously that the aSPU test could control its type I error rate effec-
tively in the context of unweighted association testing (Pan et al 2014), which is expected
to hold in the current context. Nevertheless, we conducted a simulation study to confirm
it. We used the individual-level (imputed) genotypic data of the WTCCC control and
T2D samples with a combined sample size of n = 4862. We randomly generated a binary
trait with an equal probability 0.5 for each subject, and calculated a summary Z statis-
tic for each SNP. We then applied the aSPU test along with the asymptotic SPU(1)
and SPU(2) tests to the individual-level data with the same PrediXcan-constructed
weights based on the DGN whole blood gene expression data; in addition, we also ap-
plied the tests to the summary Z-statistics with the TWAS-constructed weights based
on the NTR, YFS and METSIM gene expression data respectively; finally, we applied
the omni-bus aSPU-O test to the summary statistics to combine results across the three
sets of NTR, YFS and METSIM weights. As shown in the Q-Q plots in Figure 5.10, in
each case each test controlled the type I error rate satisfactorily.
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5.4 Conclusions
In summary, we have developed a powerful adaptive test (aSPU) to integrate GWAS
and eQTL data. We have demonstrated its improved power over the existing methods;
in fact, the same association test underlying the two existing methods, PrediXcan and
TWAS, can be regarded as a special case of our proposed test, explaining why our
proposed test may have improved power.
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Figure 5.1: The Manhattan plots for the pooled results of aSPU and aSPU-O for traits
HDL (top) and LDL (bottom) based on the 2013 lipid data. The letters “(n)”, “(y)”,
“(m)” and “(o)” following a gene’s name indicate the result of aSPU based on the NTR,
YFS and METSIM weights and that of aSPU-O respectively.
77
0
2
4
6
8
10
12
Chromosome
−
lo
g 1
0(p
)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 22
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
llll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
ll
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
ll
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
llll
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
ll
l
l
l
l
ll
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
ll
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
l
ll
l
llll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
llll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
lll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
llll
l
l
l
lll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
llll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
lll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
llll
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
ll
l
ll
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
ll
ll
l
ll
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
ll
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
PABPC4(y)
DOCK7(y)
SLC5A6(y)
ATRAID(m)
SNX17(y)
NRBP1(m)
KRTCAP3(y)
KRTCAP3(m)
KRTCAP3(o)
AFF1(m)
HSD17B13(o)
HSD17B13(m)
FLOT1(y)
FLOT1(n)
FLOT1(o)
IER3(y)
IER3(n)
IER3(o)
VARS2(y)
HCG27(y)
HCG27(m)
HCG27(o)
HLA−C(y)
HLA−C(o)
HLA−B(n)
HLA−B(o)
MICA(m)
MICA(o)
MICB(y)
MICB(o)
BAT1(n)
NCR3(y)
DDAH2(y)
C6orf48(m)
SLC44A4(n)
EHMT2(y)
SKIV2L(m)
DOM3Z(y)
STK19(y)
NOTCH4(y)
HLA−DRA(y)
HLA−DRA(n)
HLA−DRA(o)
HLA−DQA1(o)
HLA−DRB5(n)
HLA−DRB5(o)
HLA−DQA1(y)
HLA−DQA1(m)
HLA−DQA2(y)
HLA−DQA2(o)
TAP2(o)
SNX10(m)
TBL2(y)
MLXIPL(m)
ABHD11(o)
NEIL2(n)
NEIL2(o)
CSGALNACT1(n)
CSGALNACT1(o)
CSGALNACT1(y)
CSGALNACT1(m)
LPL(y)
LPL(n)
LPL(o)
ARHGAP1(m)
NR1H3(y)
C11orf10(n)
FADS1(y)
FADS2(n)
PAFAH1B2(n)
SIDT2(y)
SIDT2(m)
SIDT2(n)
SIDT2(o)
TAGLN(y)
TAGLN(n)
PCSK7(y)
PCSK7(m)
PCSK7(o)
CCDC92(m)
CCDC92(o)
NPIPA1(m)
HSD3B7(y)
ZNF668(y)
HERPUD1(y)
GATAD2A(n)
GATAD2A(o)
GATAD2A(y)
GMIP(y)
PLTP(m)
MMP9(y)
HMGN2(m)
ARID1A(n)
ZDHHC18(y)
LRPAP1(o)
HSD17B13(n) HSD17B13(y)
POU5F1(m)
AIF1(y)
HLA−DOB(n)HLA−DOB(y) HLA−DOB(m)
TAP2(y)
TAP1(y)
RPS18(y)
MSRA(n)
FDFT1(m)
ACP2(m)
SPI1(y)
LCMT2(y)
KAT8(m)
BLOC1S3(m)
DDX17(n)
0
2
4
6
8
10
Chromosome
−
lo
g 1
0(p
)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 22
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
lll
ll
lll
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
llll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
llll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
llll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
ll
ll
l
lll
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
llll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
lll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
lll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
RHD(m)
RHCE(o)
TMEM50A(o)
RHCE(m)
DOCK7(y)
CELSR2(m)
PSRC1(y)
PSRC1(o)
SORT1(n)
SYPL2(m)
CYB561D1(y)
AMIGO1(m)
GSTM4(y)
GSTM4(n)
GSTM4(o)
SLC5A6(y)
SNX17(y)
NRBP1(m)
KRTCAP3(m)
KRTCAP3(o)
MCM6(o)
DARS(o)
ICA1L(m)
TIMP4(m)
MKRN2(o)
MKRN2(y)
POLK(m)
POC5(m)
FLOT1(y)
FLOT1(n)
FLOT1(o)
IER3(y)
IER3(n)
IER3(o)
HCG27(y)
HCG27(o)
HLA−B(n)
HLA−B(o)
MICA(m)
MICA(o)
MICB(y)
MICB(o)
BAT1(n)
DDAH2(y)
C6orf48(m)
SLC44A4(n)
SKIV2L(m)
SKIV2L(o)
DOM3Z(y)
STK19(y)
NOTCH4(y)
HLA−DRA(y)
HLA−DRA(n)
HLA−DRA(o)
HLA−DRB5(n)
HLA−DRB5(o)
HLA−DRB1(o)
HLA−DQA2(o)
TAP2(n)
TAP2(o)
TAP1(y)
FRK(m)
NT5DC1(m)
NT5DC1(o)
WTAP(m)
SLC22A1(m)
GPR146(y)
NUDCD3(m)
NPC1L1(m)
DDX56(y)
TMED4(y)
ERI1(n)
NSMAF(y)
NRBP2(y)
PARP10(y)
PARP10(o)
TTC39B(o)
VIM(y) PTPRJ(n)
C11orf10(n)
FADS1(y)
FADS2(n)
PAFAH1B2(n)
SIDT2(y)
SIDT2(m)
SIDT2(n)
SIDT2(o)
TAGLN(y)
PCSK7(y)
PCSK7(m)
PCSK7(o)
ALDH2(n)
ALDH2(o)
ALDH2(y)
OASL(y)
CDK2AP1(o)
SETD8(y)
HERPUD1(y)
LCAT(y)
NFATC3(y)
ESRP2(n)
ATXN1L(y)
KIAA0174(n)
DHODH(m)
HP(m)
HP(o)
DHX38(y)
DHX38(m)
DHX38(o)
PGAP3(m)
PGAP3(o)
TBKBP1(y)
S1PR5(y)
CARM1(y)
SMARCA4(n)
TSPAN16(n)
EPOR(y)
GATAD2A(n)
GATAD2A(o)
GATAD2A(y)
LPAR2(o)
GMIP(y)
CEACAM19(m)
PVRL2(n)
PVRL2(o)
BLOC1S3(m)
NTN5(m)
LILRA3(n)
LILRA3(o)
LILRA3(y)
CPNE1(n)
TCEA3(m)
ARID1A(n)
GNAI3(y)
GSTM4(m)
ATRAID(m) KRTCAP3(y)
MCM6(y)MCM6(n)
DARS(m)
PARP9(y)
PCCB(o)
LRPAP1(o)
VARS2(y)
HLA−C(y)
HLA−DQA1(y)
HLA−DQA2(y)
SNRPC(o)
TSPYL1(m)
ADAP1(y)
GPR146(n)
AEBP1(y) UBXN2B(y)
PLEC(m)
GRINA(n)
GRINA(y)
PARP10(m)
TTC39B(n)
TTC39B(y)
C1QTNF4(m)
TAGLN(n) SH2B3(y)
ATXN2(y)
CDK2AP1(n)
CDK2AP1(y)
MPI(y)
ZNF668(y)
OGFOD1(m)
DPEP3(n)
DUS2(m)
PHLPP2(y)
HP(n)
PFAS(y)
FBXL20(y)
PGAP3(y)
IKZF3(n)
GSDMB(y)
ORMDL3(y)
TBKBP1(m) PPP5C(m)
CPNE1(m)
RBM39(y)
UBE2L3(y)
TOM1(n)
TOM1(y)
Figure 5.2: The Manhattan plots for the pooled results of aSPU and aSPU-O for traits
TG (top) and TC (bottom) based on the 2013 lipid data.
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Figure 5.3: The scatter plots of the base 10 − log(p-values) of the SPU(1) test and PrediXcan
applied to the WTCCC data with weights derived from the DGN whole blood for traits CD,
BD, CAD, RA, HT, T1D and T2D (from the left to the right and the top to the bottom). The
Pearson correlation coefficient between the two sets of the -log p-values in each panel was equal
to 1. For better visualization, all the p-values were truncated at 1× 10−9.
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Figure 5.4: The Q-Q plots applied to the WTCCC data with the weights derived from the
DGN whole blood gene expression for traits CD, BD, CAD, RA, HT, T1D and T2D (from the
left to the right and the top to the bottom). The second column in each legend indicates the
numbers of the significant genes identified at the genome-wide significance level of 5.56× 10−6.
For better visualization, the p-values of aSPU were truncated at 1 × 10−7, while those of the
other two asympototic tests were truncated at 1× 10−9.
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Figure 5.5: The scatter plots of the base 10 − log(p-values) of the SPU(1) test and TWAS applied to 2010
lipid data with each set of the weights based on the NTR, YFS and METSIM studies, corresponding to the 1st,
2nd and 3rd columns, respectively. The panels from the top row to the bottom row correspond to traits HDL,
LDL, TC and TG, respectively. The Pearson correlation coefficients in each panel was equal to 1. For better
visualization, all the p-values were truncated at 1× 10−9.
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Figure 5.6: The Q-Q plots for the 2010 lipid data with each of the weights NTR, YFS and METSIM,
corresponding to the 1st, 2nd and 3rd columns, respectively. The panels from the top row to the bottom row
correspond to HDL, LDL, TC and TG, respectively. For better visualization, the p-values of aSPU were truncated
at 1× 10−7, while those of the other two asympototic tests were truncated at 1× 10−9.
82
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    22
SPU(1)  21
SPU(2)  23
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    52
SPU(1)  35
SPU(2)  51
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    33
SPU(1)  24
SPU(2)  33
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    24
SPU(1)  16
SPU(2)  24
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    40
SPU(1)  28
SPU(2)  42
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    27
SPU(1)  16
SPU(2)  30
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    36
SPU(1)  25
SPU(2)  39
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    70
SPU(1)  38
SPU(2)  69
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    42
SPU(1)  26
SPU(2)  43
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    21
SPU(1)  15
SPU(2)  23
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    43
SPU(1)  27
SPU(2)  43
0 1 2 3 4 5
0
2
4
6
8
−log10(Expected)
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
0
2
4
6
8
−
lo
g1
0(O
bs
erv
e
d)
aSPU    26
SPU(1)  15
SPU(2)  25
Figure 5.7: The Q-Q plots for the 2013 lipid data with each of the weights NTR, YFS and METSIM,
corresponding to the 1st, 2nd and 3rd columns, respectively. The panels from the top row to the bottom row
correspond to HDL, LDL, TC and TG, respectively. For better visualization, the p-values of aSPU were truncated
at 1× 10−7, while those of the other two asympototic tests were truncated at 1× 10−9.
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Figure 5.8: The Manhattan plots of aSPU (top) and TWAS (bottom) applied to the 2013 lipid dataset with
trait LDL and the YFS-based weights. The p-values of both aSPU and TWAS were truncated at 1× 10−7.
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Figure 5.9: The Manhattan plots of aSPU-O (top) and TWAS-O (bottom) applied to the 2013 lipid dataset
for trait LDL and combining over the three sets of the weights. The p-values of both aSPU-O and TWAS-O were
truncated at 1× 10−7.
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Figure 5.10: The Q-Q plots for the WTCCC genotypic data and a randomly simulated binary
trait. (a) Results with the individual level data and the weights derived from the DGN whole
blood gene expression; (b-d) the results with the summary statistics and the weights derived from
the NTR, YFS and METSIM studies, respectively; (e) the results with the summary statistics
and combining the three sets of the weights. For (a) - (d), the three numbers in each parenthesis
correspond to inflation factors of aSPU, SPU(1) and SPU(2), respectively; for (e), the number
in the parenthesis corresponds to the inflation factor of aSPU-O. For better visualization, the
p-values of aSPU were truncated at 1 × 10−7, while those of the other two asympototic tests
were truncated at 1× 10−9.
Table 5.1: Significant genes identified by the aSPU test, but not by the SPU(1) test
(or PrediXcan) at the genome-wide significance threshold of 5.56×10−6. The validated
gene-trait associations appeared in the following references: [1] Franke et al ( 2010); [2]
Kenny et al (2012); [3] Plagnol et al (2011).
SNPs in Reported
Trait Gene Chr. #SNPs aSPU SPU(1) SPU(2) Valid. ref
CD IRGM 5 34 5.0E-07 1.7E-04 3.8E-08 CD [1]
P4HA2 5 7 2.5E-06 1.7E-01 8.4E-07 CD [2]
PTGER4 5 22 1.1E-06 1.0E-05 2.6E-07 CD [1]
RBM22 5 15 7.0E-07 1.4E-02 5.5E-06 -
BD JAKMIP1 4 21 1.0E-07 1.8E-05 3.2E-09 -
CAD PDK1 2 33 5.5E-06 5.8E-03 2.7E-05 -
T1D ALDH2 12 19 1.0E-07 6.6E-05 1.1E-07 -
BCL2L15 1 21 1.0E-07 5.1E-04 2.1E-06 T1D [3]
HFE 6 61 7.0E-07 5.8E-01 5.7E-08 -
MPHOSPH10 2 20 6.0E-07 1.2E-01 1.4E-07 -
PGBD1 6 33 1.0E-07 3.0E-04 2.4E-09 -
PRSS16 6 32 1.5E-06 6.3E-05 2.0E-07 -
TMEM116 12 23 2.0E-06 5.0E-04 6.9E-07 -
ZNF193 6 64 1.0E-07 2.3E-02 5.0E-11 -
ZSCAN12 6 14 4.0E-07 8.1E-06 2.5E-06 -
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Table 5.2: The numbers of the significant genes identified by analyzing the 2010 lipid
data for each single set of the weights and the combined one (i.e. with the omnibus
aSPU and TWAS tests). The numbers a/b/c in each cell indicate the numbers of (a) the
significant genes; (b) the significant genes that covered a genome-wide significant SNPs
in the 2010 lipid data; (c) the significant genes that covered a genome-wide significant
SNPs in the 2013 lipid data.
Trait Test NTR YFS METSIM Combined
HDL aSPU 19/16/17 29/27/29 22/19/22 21/17/17
TWAS 16/14/15 25/22/24 19/15/19 20/16/17
LDL aSPU 15/15/15 19/18/18 17/16/17 14/13/13
TWAS 8/7/8 10/9/9 7/7/7 7/7/7
TG aSPU 17/16/17 33/30/32 15/14/14 20/19/19
TWAS 9/9/9 17/16/17 8/7/7 12/11/11
TC aSPU 26/25/26 28/26/27 28/28/28 20/20/20
TWAS 15/14/15 18/16/17 15/14/15 14/13/13
Table 5.3: The numbers of the significant genes identified by analyzing the 2013 lipid
data for each single set of the weights and the combined one (i.e. with the omnibus
aSPU and TWAS tests). The numbers a/b/c in each cell indicate the numbers of (a) the
significant genes; (b) the significant genes that covered a genome-wide significant SNPs
in the 2010 lipid data; (c) the significant genes that covered a genome-wide significant
SNPs in the 2013 lipid data.
Trait Test NTR YFS METSIM Combined
HDL aSPU 21/18/21 52/39/48 33/24/32 31/21/29
TWAS 21/17/20 35/26/33 24/17/23 26/16/24
LDL aSPU 24/23/24 40/34/37 27/24/26 20/17/18
TWAS 16/14/16 28/23/25 16/14/15 17/15/16
TG aSPU 21/19/21 43/37/42 26/20/25 23/21/23
TWAS 15/13/15 27/22/25 15/12/15 16/15/16
TC aSPU 36/27/35 70/52/66 42/36/42 37/32/36
TWAS 25/18/24 38/28/35 26/21/26 25/20/23
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Table 5.4: Significant gene-trait associations identified by aSPU or/and TWAS with
no known risk loci within 500kb. The column “Sig.test” indicates the corresponding
association was detected by aSPU or SPU(1) or both.
Trait Weight Gene Chr. Locus start Locus end aSPU SPU(1) SPU(2) Sig.test
HDL YFS SLC41A1 1 205758221 205782876 4.5E-06 7.9E-04 2.2E-04 aSPU
HDL YFS ASCC2 22 30184597 30234271 6.0E-07 9.7E-04 6.2E-06 aSPU
LDL YFS PFAS 17 8150936 8173809 5.1E-06 4.2E-03 1.1E-06 aSPU
TG METSIM ARHGAP1 11 46698630 46722165 1.0E-07 3.8E-04 1.2E-08 aSPU
TC YFS ZNF668 16 31072164 31085641 2.1E-06 3.7E-05 1.4E-05 aSPU
TC YFS PFAS 17 8150936 8173809 2.9E-06 5.4E-03 1.8E-06 aSPU
LDL YFS HSPA6 1 161494036 161496681 2.8E-05 4.6E-06 3.2E-02 SPU(1)
TG YFS PACS1 11 65837834 66012218 8.2E-06 5.7E-06 1.2E-06 SPU(1)
TC YFS ADCY3 2 25042038 25142708 1.1E-05 4.1E-06 2.5E-02 SPU(1)
HDL NTR RETSAT 2 85569078 85581848 2.2E-06 1.3E-06 2.3E-06 Both
HDL YFS RETSAT 2 85569211 85581743 2.0E-06 2.3E-06 1.5E-06 Both
HDL YFS PTPRE 10 129705325 129884119 1.0E-07 3.7E-08 1.4E-01 Both
HDL METSIM SNX10 7 26331541 26413949 8.0E-07 5.6E-07 8.7E-07 Both
LDL YFS ERAL1 17 27181956 27188085 2.8E-06 1.7E-06 2.2E-06 Both
LDL YFS DHRS13 17 27224799 27230089 4.1E-06 2.2E-06 2.4E-06 Both
LDL METSIM ICA1L 2 203640690 203736708 7.0E-07 2.1E-07 5.9E-07 Both
TG YFS LCMT2 15 43619974 43622803 1.8E-06 1.6E-06 3.2E-06 Both
TC NTR ARID1A 1 27022521 27109023 1.2E-06 9.7E-07 1.4E-06 Both
TC YFS PARP9 3 122246771 122283424 4.9E-06 2.4E-06 3.7E-06 Both
TC YFS MPI 15 75182346 75191798 4.3E-06 6.1E-07 6.8E-07 Both
Chapter 6
Discussion and future work
As it is not feasible to apply the existing score-based testing under complex models due
to either the lack of a close-form solution of score vectors or no software output, Chap-
ter 2 introduced a method to approximate the score vector by MLEs. Our proposed
general approach is a two-step procedure. In the first step, a full model including a set
of parameters to be tested is fitted, then in the second step the score vector for the pa-
rameter and its covariance matrix are approximated based on the parameter estimates
and their covariance matrix. In this way, a score-based test can be applied without
directly calculating the score vector (and its covariance matrix), which may not be easy
to derive based on existing software packages, such as for mvLMM and GLMM. Due to
the nature of the proposed two-step approach, the validity of the approach depends on
both the first step and the asymptotics. For example, if we have a familial dataset with
trait-ascertained samples, then it is necessary to appropriately account for the sample
ascertainment in step one, e.g., based on some family-based association testing proce-
dures [Moerkerke et al., 2010; Zhang et al., 2012]. Furthermore, because the proposed
approximation to the score vector is based on the asymptotics of the parameters to be
tested, it has some limitations. First, if the sample size is too small or more generally,
if the conditions for the asymptotics do not hold, e.g., in analysis of rare variants [Chen
et al., 2013; Jiang et al., 2014], then it may not perform well with inflated false posi-
tives and false negatives. Second, in order to obtain a point estimate of the parameters
to be tested, a full model has to be fitted, which may not be even computationally
feasible if the number of the parameters to be estimated is too large relative to the
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sample size. Nevertheless, the proposed method offers a simple and practical way to
extend many score-based tests to more complex models, for which the score vector is
either unavailable from software or has no closed-form solution. In addition to testing
for main effects as considered here, it will also be interesting to explore the use of the
proposed method to detect gene-gene and gene-environment interactions [Tzeng et al.,
2011]. For example, the Minnesota Twin Family Study (MTFS) is a longitudinal study
of twins and their parents to examine factors to the etiology of substance abuse and
related problelms [Lacono and McGue, 2002]. An application of our proposed method
would be to study the associations between clinical phenotype (e.g nicotine factor, al-
cohol consumption factor, drug factor etc.) and genetic variations accounting for both
genetic and (shared) environmental factors. There are several challenging while very
interesting problems of modeling this family data. First, as twins families share not
only genetic but also environment, both genetic and shared environmental factors need
to be taken into consideration. Second, as MTFS is a longitudinal study, each pheno-
type (e.g. nicotine factor) has multiple time points. Thus, how to model longitudinal
phenotype while accounting for genetic and shared environment factors is an interesting
question. Third, as some of phenotypes might be correlated, it may help to gain power
to consider multiple traits in association analysis. Li et al. [2011] proposed a generalized
least squares approach for genome-wide quantitative trait association analysis in fam-
ilies, which is a feasible and efficient model providing both genetic and environmental
variance estimates. Instead of modeling the clinical phenotype at a single time point,
we can treat the longitudinal phenotype as multiple phenotypes and fit a multivariate
linear mixed model (e.g. by GEMMA) by supplying the genetic and environmental vari-
ance estimated from RFGLS. Another way to model the twins family data is that we
can model multiple phenotypes (e.g. nicotine factor, drug factor and alcohol consump-
tion factor) by linear mixed-effects model approaches. At the end, based on the MLE
by fitting the mixed-effects models, we can construct the approximated score vectors
accordingly and conduct score-based testing (e.g aSPU test).
In Chapter 3, we showed that potential power gain could be achieved by accounting
genetic heterogeneity. As integrative analysis of multiple types of data may provide more
information to capture the disease heterogeneity, our future work could develop a novel
machine learning method to discover the subpopulations for a disease of interest. For
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example, ADNI data consists of structural and functional magnetic resonance imaging
(sMRI and fMRI), single-nucleotide polymorphism (SNP)/genotyping and messenger
ribonucleic acid (mRNA) etc. Rather than considering unknown genetic genterogene-
ity here, we may utilize mRNA data, for example, to identify the subpopulations in
patient group and conduct association testing accounting on the identified “known”
subpopulation, which may increase power.
Motivated by a reformulation of RV test, we proposed a new method aSPC to test
association between two random vectors in Chapter 4. In the current implementation
of the new tests, we have resorted to permutations to calculate their P-values, which
seems feasible and satisfactory in many applications. However, it would be interesting
to establish their asymptotics as both p and q diverge with n (Xu et al 2016), which may
be challenging due to the dependencies among the individual correlation coefficients in
each SPC test statistic. Nevertheless, an asymptotic theory will be useful in facilitating
speedy P-value calculations, especially for a high significance level.
Chapter 5 introduced a statistical method integrating eQTL and GWAS (summary
or individual level) data. Importantly, our new formulation of PrediXcan and TWAS
suggests other possible extensions, e.g. applications not only to other informative en-
dophenotypes, but also to incorporate other sources of information like previous linkage
scans (Roeder et al 2006) and multiple phenotypes (Kim et al 2015; Zhu et al 2015),
which will be investigated in the future.
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